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ABSTRACT: Human African trypanosomiasis is causing thousands of deaths every
year in the rural areas of Africa. In this manuscript we describe the optimization of a
family of phtalazinone derivatives. Phosphodiesterases have emerged as attractive
molecular targets for a novel treatment for a variety of neglected parasitic diseases.
Compound 1 resulted in being a potent TbrPDEB1 inhibitor with interesting activity
against T. brucei in a phenotypic screen. Derivative 1 was studied in an acute in vivo
mouse disease model but unfortunately showed no efficacy due to low metabolic
stability. We report structural modifications to achieve compounds with an improved
metabolic stability while maintaining high potency against TbrPDEB1 and T. brucei.
Compound 14 presented a good microsomal stability in mouse and human
microsomes and provides a good starting point for future efforts.
■ INTRODUCTION
Human African trypanosomiasis (HAT), or African sleeping
sickness, is caused by the unicellular parasites of the species
Trypanosoma brucei (T.brucei). The vector that propagates this
disease is the tsetse fly, found mainly in rural Africa. The
disease is divided in two different subtypes: gambian sleeping
sickness (Trypanosoma brucei gambiense) and rhodesian
sleeping sickness (Trypanosoma brucei rhodesiense). The first
one is chronic and can take years to fatality, while the second
one is an acute illness causing death within weeks or months
after the infection.1 In both forms, the late stage of the disease
is characterized by the entrance of the parasite into the central
nervous system with fatal consequences if untreated. Although
the two forms affect human beings, 98% of the cases of
sleeping sickness are caused by T.brucei gambiense, which
predominates in central and western African countries.2
HAT belongs to the family of NTDs (neglected tropical
diseases), and these sicknesses contribute to a high level of
morbidity and mortality in the third world countries (550 000
deaths per year).3 The investment from pharmaceutical
companies to achieve new molecules capable to cure those
diseases is not sufficient. For this reason research from public
institutions to develop new drugs that are safe and easy to
administer is crucial.
To develop new molecules able to cure this disease, a
public−private consortium has been established funded by the
European Union. This project, named “Parasite-Specific Cyclic
Nucleotide Phosphodiesterase Inhibitors To Target Neglected
Parasitic Diseases”, has validated parasitic cyclic nucleotide
phosphodiesterases as valuable targets for drug discovery and
has identified parasite-specific features of the PDE active sites.4
PDEs have emerged as attractive molecular targets for a
novel treatment for a variety of neglected parasitic diseases,
including African trypanosomiasis, Chagas disease, and
malaria.5
The genome of T.brucei presents five trypanosomal cyclic
nucleotide phosphodiesterases.6 For sleeping sickness,
TbrPDEB1 and TbrPDEB2 were genetically validated as
drug targets.7 These enzymes are different from the human
form since they have a subpocket, named as the parasite
specific pocket or the P-pocket, in the substrate binding site.8
This pocket potentially offers an area that can be targeted to
impart selectivity, avoiding side effects related to inhibition of
the human off-targets. For instance, inhibition of hPDE4 yields
side effects such as nausea and emesis.9 Moreover, inhibition of
human PDE4 (hPDE4) attenuates the immune system via
inhibition of TNFα, which is certainly undesirable in rural
Africa.10−12
In previous investigations carried out by de Koning et al, a
phenylpyridazinone derivative was discovered from a high
throughput screening campaign (PPS54019, compound A)
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and was validated as a TbrPDEB1 and TbrPDEB2 inhibitor.13
This compound (now renamed as NPD-001) was previously
designed as hPDE4 inhibitor.14 It has been used as a hit
compound to develop new families of TbrPDE inhibitors with
Figure 1. Structure of the TbrPDEB1 inhibitor, compound 1. This compound was evaluated in a phenotypic panel including T. brucei and MRC5
to study if the compound is selective over human cells. In addition, it was evaluated on the isolated enzymes TbrPDEB1 and hPDE4. The mouse
microsomal stability reveals the need to improve the stability of this compound.
Figure 2. Main metabolic hot spots predicted by the Meteor program.
Figure 3. Derivatives of compound 1 designed to improve metabolic stability.
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improved selectivity over hPDE4 isoforms.15,16 From an
unpublished library of compounds belonging to this family,
compound 1 (Figure 1) was selected as one of the more
promising ones because it is a potent TbrPDEB1 inhibitor with
interesting activity against T. brucei in a phenotypic assay and
low cytotoxicity. In a proof of concept study, compound 1 was
used in an acute in vivo mouse disease model on Swiss mice
infected with 104 trypanosomes T. brucei at a daily dosing of 50
mg/kg ip or 50 mg/kg po. However, it showed no efficacy
because of its low metabolic stability (Figure 1). In this paper,
we report structural modifications to achieve compounds with
an improved metabolic stability while maintaining high
potency against TbrPDEB1 and T. brucei.
To get a better understanding of the metabolic hot spots in
compound 1, the theoretical metabolites resulting from phase
1 metabolism were predicted by using the Meteor program
(Figure 2).
■ RESULTS
Chemistry. On the basis of the metabolic hotspots of
compound 1, we designed different molecules to improve the
metabolic stability (Figure 3).
Modification of the methoxy groups to avoid O-
demethylation was carried out by introducing fluorine or
chlorine atoms. Changes in the core of the molecule were also
performed to study the importance of the phthalazinone
scaffold in the activity and stability. The saturated form of the
phthalazinone was obtained to avoid allylic hydroxylation.
Diverse heterocycles were introduced mimicking a purine
moiety to benefit from an active uptake in the parasite by the
nucleoside P2 transport system.17−19
Different synthetic approaches were followed depending on
the final compound. In general, (4aS,8aR)-4-(3,4-dimethox-
yphenyl)-2-(piperidin-4-yl)-4a,5,8,8a-tetrahydrophthalazin-
1(2H)-one was used as starting material (Scheme 1) to
introduce the different heterocycles.
Another modification concerning this part of the molecule is
the ring size of the imide and its substitution pattern. These
compounds were synthesized as previously described (Scheme
2).20
It is well-known that methoxyphenyl derivatives can be
rapidly metabolized through oxidative O-demethylation during
phase I metabolism. In an attempt to avoid this, the two
methoxy substituents were replaced by different halogen atoms
or by introducing a difluoromethoxy moiety. Fluorine atoms
have been used extensively in medicinal chemistry programmes
to improve ADME properties of molecules.21−23
The introduction of a fluorine or chlorine atom in the
phenyl ring was performed following the reactions described in
Scheme 3.14
Furthermore, difluoromethoxy moieties were explored
instead of the methoxy groups. This reaction was performed
as previously described (Scheme 4).24 A demethylation in the
presence of BBr3 was carried out, followed by difluoromethy-
lation of the diphenol derivative.
This modification was also performed for some of the
heterocycle substituted derivatives, leading to three different
compounds (Scheme 5).
The phthalazinone core was also replaced aiming to remove
the different stereocenters and to improve synthetic feasibility.
The imidazotriazinone was synthesized following the proce-
dure already described.25 After the reaction of the imidazole
and the acyl chloride, the cyclization of the compound in the
presence of p-toluensulfonic acid was carried out. Once the
new core scaffold was obtained, the molecule was modified as
previously (Scheme 6).
Because the double bond of the phthalazinone can be
sensitive to epoxidation and allylic oxidation in phase I
metabolism, the most promising compounds were also
modified by removing this double bond by hydrogenation in
the presence of Pd(C) (Scheme 7).
Scheme 1a
aReaction conditions: (i) heteroaryl chloride, Et3N, K2CO3, DMF,
153 °C, 2−18 h.
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In order to decrease the molecular weight, two other
scaffolds were also explored. A pyridazinone was synthesized as
described in Scheme 8. The already described pyrazolone core
was obtained using the synthesis described in Scheme 9.26
The last modification was the replacement of the piperidine
ring by an azetidine ring using a very similar synthetic pathway
(Scheme 10).
In Vitro Evaluation of the Compounds against
TbrPDEB1, hPDE4, T. brucei. All obtained compounds
were evaluated against a parasite panel including Trypanosoma
brucei, Trypanosoma cruzi, Leishmania Infantum, Plasmodium
falciparum. Cytotoxicity was determined against a human cell
line (MRC5) and peritoneal macrophages from mouse
(PMM) (Figure 4 and Table 1, full panel in Supporting
Information).
Furthermore, most of the compounds were evaluated on the
purified catalytic domain of TbrPDEB1 enzyme. As a measure
of the selectivity, inhibition of the catalytic domain of the
human PDE4 for compounds with pKi > 6 on TbrPDEB1 was
determined.
Structure−Activity Relationship (SAR). In general, the
compounds that were active in the phenotypic panel against T.
brucei also presented potency on the isolated catalytic domain
of the TbrPDEB1 enzyme. This suggests that the compounds
are working through PDE inhibition. There are also some
compounds that do not present activity in the phenotypic
panel but present potency on the enzyme (compounds 16 and
28) which might be caused by lack of membrane permeability.
Among all the modifications that have been introduced, we
observe that the preferred core scaffold is the saturated or
unsaturated phthalazinone (compound 11 vs 43 or 51). As
linker between the phthalazinone and the imide or heterocycle,
a piperidine is clearly favored over an azetidine with a 3- to 10-
fold loss in potency against both T. brucei and TbrPDEB1
(compound 1 vs 61, 12 vs 59, or 17 vs 62).
Regarding the substituents in the phenyl ring, the methoxy
groups are the most favorable ones (compound 1 vs 32 or 35).
When the OMe moiety is substituted by Cl, the potency on
PDEB1 decreases about 20-fold (compound 11 vs 24). When
the substitution is H,F or F,F, compounds are inactive on
PDEB1 except compound 28; however, this compound did not
show activity on the antiparasitic panel. On the other hand,
OCHF2 substitution maintains antiparasitic activity (com-
pound 35 vs 1) although a 1-fold loss of activity on PDEB1 is
observed. Furthermore, when the chain is longer (compound
36 vs 17), the potency on both PDEB1 and the parasitic panel
decreases when the OCHF2 is present. For the heterocyclic
ring attached to the piperidinyl, the thienopyrimidine-2-amino
(compound 11) maintains the activity on the phenotypic panel
and presents a lower pIC50 against the human cell line MRC5;
compared with the hit compound 1, it is also as potent on
PDEB1 as compound 1. When an amino substituent is added
to the quinazoline ring (compound 7 vs 12, and 4 vs 6), the
activity on PDEB1 increases or is maintained while the activity
on the phenotypic panel decreases. Regarding the imide
moiety, when the six-membered ring is changed by a five-
Scheme 2b
aCalculated yield for the last step of the reaction. bReaction conditions: (i) Et3N, K2CO3, THF, rt, 2 h; (ii) imide derivative, K2CO3, DMF.
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membered ring (compound 1 vs 15) the phenotypic activity
decreases while the potency on PDEB1 is kept. Also, when
another six-membeed ring is fused, the activity is higher on
PDEB1 and it is maintained on the phenotypic panel. This
behavior is only valid when the substitution on the phenyl ring
is OMe, OMe (compound 17 vs 31 or 1 vs 32).
Metabolic Stability. Metabolism plays an important role
in the development of a drug candidate; it impacts on
Scheme 3b
aCalculated yield for the last step of the reaction. bReaction conditions: When X = Cl, Y = OMe, and R = H: (i) AlCl3, DCM, rt, overnight; (ii) 4-
hydrazinylpiperidine dihychloride, Et3N, EtOH, 80 °C, overnight; (iii) 4-chloro-2-aminothieno[2,3-d]pyrimidine, K2CO3, DMF, 120 °C, 16 h.
When X = H and Y = F or X = Y = F, R = MgBr: (i) (3aR,7aS)-3a,4,7,7a-tetrahydroisobenzofuran-1,3-dione, THF, rt, 16 h; (ii) 4-
hydrazinylpiperidine dihydrochloride, Et3N, EtOH, 80 °C, 16 h; (iii) heteroaryl chloride, K2CO3, DMF, 120 °C, 3−16 h or 2-chloroacetyl chloride,
Et3N, DCM, 0 °C, 30 min followed by 2,6-dione derivative, K2CO3, DMF, 100−120 °C, 1−16 h.
Journal of Medicinal Chemistry pubs.acs.org/jmc Article
https://dx.doi.org/10.1021/acs.jmedchem.9b00985
J. Med. Chem. 2020, 63, 3485−3507
3489
pharmacokinetic parameters such as oral bioavailability,
clearance, and half-life. This will affect the efficacy and
toxicology of the drug due to changes in the concentrations
within plasma and tissues.27
To evaluate phase I and phase II metabolism of the
compounds, mouse and human microsomes were used.
Compounds with structural differences have been selected to
be studied in mouse and microsomes. With the mouse
microsomes results, some of those compounds with promising
stability or important structural changes were selected to be
evaluated in human microsomes. In Figure 5, mouse and
human microsomal stabilities at different time points are
represented. Full data with standard deviation are shown in the
Supporting Information.
From these results, we can conclude that the different
regions of the molecules contribute to differences in stability.
In general, the saturated phthalazinone core is more stable than
the unsaturated one (compounds 48 vs 1, 47 vs 31, and 49 vs
35), and the piperidinyl also increases the stability compared
to the azetidine residue (compound 17 vs 62). Regarding the
Scheme 4b
aCalculated yield for the last step of the reaction. bReaction conditions: (i) BBr3, DCM, −40 °C, 2 h; (ii) diethyl (bromodifluoromethyl)-
phosphonate, KOH, acetonitrile/water, −40 °C, 45 min; (iii) 2,6-dione derivative, K2CO3, DMF, 120 °C, 16 h.
Scheme 5b
aCalculated yield for the last step of the reaction. bReaction conditions: (i) BBr3, DCM, −40 °C, 2 h; (ii) diethyl (bromodifluoromethyl)-
phosphonate, KOH, acetonitrile/water, 45−120 min at −40 °C and 2−16 h at rt.
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substituents of the phenyl ring, generally, the substitution of
the methoxy group by difluoromethoxy moieties or fluorine
atoms also enhances the stability (compound 5 vs 25, 26, 27,
38, and 39), suggesting that the catechol moiety suffers from
oxidative O-demethylation. Also the imide ring size and
substitution pattern influences metabolic stability.
Compound 14 presented a good metabolic stability profile
in mouse (43% of parent compound remaining after 30 min)
and human microsomes (89% after 30 min). It also combines
potency on the parasite (pIC50(Tbr) = 5.73) and on the
enzyme (pKi(TbrPDEB1) = 7.68) with low cytotoxicity.
However, it completely lacks selectivity over the human
enzyme (pKi(hPDE4) = 10.21). Since this will result in off-
target effects, an improved selectivity based on structure-based
drug design is necessary before we can proceed to the next in
vivo proof of concept study in the acute mouse model of T.
brucei.
X-ray Analysis of Selected Inhibitors. To get a better
understanding of their mode of interaction at the atomic level,
crystal structures of selected derivatives (Figure 6) bound to
TbrPDEB1 and hPDE4D catalytic domains were determined
by X-ray. We have chosen inhibitors that have shown good
potency in phenotypic assays or those with significant
structural modifications, together with compound 14 as the
most stable compound. Since the selected inhibitors fail to
demonstrate any selectivity over human off-target enzyme
hPDE4D, we hoped structural findings may provide us design
ideas to help improve these and other chemically similar
inhibitors.
Structures of TbrPDEB1 bound to inhibitors 1, 11, 12, 14,
and 35 were obtained in a resolution range between 1.6 and
2.5 Å (Supporting Information). In all cases, the (4aS,8aR)-
enantiomer forms of the inhibitors were observed in the crystal
structures and they display almost identical binding modes to
the parasitic enzyme (Figure 7). The phthalazinone core
occupies the area near the metal site while the substituted
phenyl group engages the hydrophobic clamp, also known as
the aromatic clamp in TbrPDEB1,7 residues Val840 and
Phe877. In addition to the aromatic stacking, the ring
substitutes further engage TbrPDEB1 via hydrogen bond
interactions involving Gln874, a residue strictly conserved
across phosphodiesterase family. The different tail groups
Scheme 6a
aReaction conditions: (i) Et3N, pyridine, rt, 16 h; (ii) p-toluensulfonic acid, toluene, diphenyl ether, ethyl hydrazinecarboxylate, 110 °C, 5 h; (iii)
tert-butyl 4-bromopiperidine-1-carboxylate, NaH, DMF, 166 °C, 48 h; (iv) TFA, DCM, rt, 16 h; (v) 4-chlorothieno[2,3-d]pyrimidin-2-amine,
Et3N, DCM, rt, 16 h.
Scheme 7a
aReaction conditions: (i) H2, Pd(C), methanol, rt, 1−72 h.
Scheme 8a
aReaction conditions: (i) tert-butyl-4-bromopiperidine-1-carboxylate,
NaH, DMF, 153 °C, 2 days; (ii) 4-chlorothieno[2,3-d]pyrimidin-2-
amine, K2CO3, Et3N, DMF, 130 °C, 16 h.
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orient themselves toward a space lined by helix-15 and the M-
loop7 and point slightly away from the parasite specific P-
pocket (Figure 7). They are largely stabilized by hydrophobic
interactions from residues located on helix-15 and the M-loop,
specially by Met861 and, to some extent, Phe880.
We have also determined structures of the hPDE4D catalytic
domain in complex with the same set of inhibitors (Supporting
Information). Their overall binding mode in hPDE4D is highly
similar to that in TbrPDEB1 with strict conservation of key
hydrophobic clamping (with Phe372 and Ile336; hPDE4D
numbering) and H-bond interactions (with Gln369; hPDE4D
numbering) in the two enzymes (Supporting Information).
Despite the overall similarity, two important observations can
be deduced from the determined inhibitor-bound structures in
TbrPDEB1 and hPDE4D, which may have implications in
future design works; first, the tail, stabilizing hydrophobic
stacking from Phe880 in TbrPDEB1, is absent in hPDE4D
with the substitution of Phe880 by Tyr375 in the equivalent
position. Second, the tail is localized close to the parasite
specific P-pocket in TbrPDEB1. In TbrPDEB1, interaction
with Phe880 may be improved by the introduction of aromatic
moieties to the existing heterocyclic tail while maintaining the
current vector direction, which may result in improved
selectivity. On the other hand, targeting the tail toward the
parasite specific P-pocket may also result in improved
selectivity over hPDE4D. The latter approach has successfully
been demonstrated in a recent work where probing the P-
pocket resulted in several-fold selectivity and led to the
discovery of first TbrPDEB1 selective inhibitors.12 As
demonstrated by the crystal structures, currently none of our
compounds are able to probe the P-pocket, explaining their
lack of selectivity for TbrPDEB1; however, localization of their
tail part close to the P-pocket is certainly encouraging, and
with a careful design approach successful targeting of the P-
pocket may well be achieved.
■ DISCUSSION AND CONCLUSIONS
Compound 1, with a submicromolar activity against T. brucei,
showed a lack of activity in the acute in vivo mouse model. This
prompted us to further modify this derivative in order to
improve the metabolic stability. The binding mode of a
selection of compounds was also studied to understand the
future modifications that can be performed in the molecule in
order to reach the P-pocket to enhance selectivity.
Different derivatives with good pIC50 values were obtained,
when the piperidinyl substituent is an imide moiety. The
nature of the phenyl substituents does not affect the activity or
the microsomal stability; the unsatured phtalazinone yields
more potent but also more unstable compounds, and the
piperidinyl linker is more favored than the azetidinyl. On the
other hand, when the piperidinyl substituent is a heterocycle,
substitution of the OMe moieties by F or OCHF2 yields better
activity values and more stable compounds; the addition of an
amino group to the heterocycle gives more stable compounds
while the potency is maintained. And as for the previous case,
the piperidinyl linker is favored over the azetidine one.
Compound 14 presented a good microsomal stability in mouse
and human microsomes and provides a good starting point for
future studies toward more selective compounds with
improved pharmacokinetic properties that can be used in an
acute in vivo T. brucei mouse model.
■ EXPERIMENTAL SECTION
Chemistry. Reagents were purchased from commercial sources
and without further purification. The products were purified with flash
chromatography on IsoleraOne flash purification system from Biotage.
Compounds were detected with UV light (254 nm). 1H NMR spectra
were obtained on a 400 MHz Bruker Avance DRX-400 and 400 MHz
Bruker Avance III NanoBay spectrometer with UltraShield. Typical
spectral parameters were the following: special width 16 ppm, pulse
width 9 μs (57°), data size 32K. 13C NMR experiments were carried
out on a 400 MHz Bruker Avance DRX-400 and 400 MHz Bruker
Avance III NanoBay spectrometer with UltraShield operating at 100
MHz. The acquisition parameters were the following: special width 16
Scheme 9a
aReaction conditions: (i) methyl isobutyrate, LDA, THF, −45 °C, 30 min, then added to 3,4-dimethoxybenzoyl chloride, from −55 °C to rt, 16 h;
(ii) N2H4, EtOH, 80 °C, 16 h; (iii) tert-butyl 4-bromopiperidine-1-carboxylate, NaH, DMF, 153 °C, 16 h; (iv) TFA, DCM, rt, 3 h; (v) 4-
chlorothieno[3,2-d]pyrimidine, NaH, DMF, 153 °C, 16 h.
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ppm, pulse width 9 μs (57°), data size 32K. Chemical shifts are
reported in values (ppm) relative to internal Me4Si, and J values are
reported in Hz. The ultraperformance liquid chromatography
(UPLC) instrument used to quantify the purity of the products was
an ACQUITY UPLC H-class system with a TUV Waters detector
coupled to a MS detector, Waters QDa. An Acquity UPLC BEH C18
1.7 μm (2.1 mm × 50 mm) column was used, and the eluent was a
mixture of 0.1% formic acid, FA, in water, 0.1% FA in acetonitrile,
water, acetonitrile. Final compounds were analyzed by high resolution
mass spectrometry. 10 μL of 10−5 M solution of each sample was
injected using the CapLC system (Waters, Manchester, U.K.) and
electrosprayed using a standard electrospray source. Samples were
injected with an interval of 5 min. Positive ion mode accurate mass
spectra were acquired using a Q-TOF II instrument (Waters,
Manchester, U.K.). The MS was calibrated prior to use with a 0.2%
H3PO4 solution. The spectra were lock mass corrected using the
known mass of the nearest H3PO4 cluster. All the compounds were
obtained as amorphous solids. All the final compounds presented a
purity at least 95% determined by UPLC and HNMR
General Synthetic Procedure for Compounds 1−12, 14−17,
25−32, 35, 36, 43, 55, 59−63. A solution of amine derivative (1
equiv), and a base, specified in every reaction, in DMF was stirred at a
fixed temperature during 1 h. After that, the alkyl reagent (1 equiv)
was added and the mixture was kept during a fixed time at a fixed
temperature specified in each case. Ethyl acetate (50 mL) and a
solution of HCl 0.1 M (50 mL) were added, and the organic phase
was washed with a satured solution of NaHCO3 (3 × 50 mL) and a
satured solution of NaCl (3 × 50 mL).
1-(2-(4-((4aS,8aR)-4-(3,4-Dimethoxyphenyl)-1-oxo-4a,5,8,8a-tet-
rahydrophthalazin-2(1H)-yl)piperidin-1-yl)-2-oxoethyl)-4,4-dime-
thylpiperidine-2,6-dione (1). Reagents: (4aS,8aR)-2-(1-(2-
chloroacetyl)piperidin-4-yl)-4-(3,4-dimethoxyphenyl)-4a,5,8,8a-tetra-
hydrophthalazin-1(2H)-one (500 mg, 1.1 mmol), 4,4-dimethylpiper-
idine-2,6-dione (202.0 mg, 1.8 mmol), potassium carbonate (493 mg,
3.57 mmol), and DMF (10 mL). Reaction conditions: 18 h at rt after
the addition of the agent. Purification: IsoleraOne using hexane/ethyl
acetate as eluents, followed by a second purification by IsoleraOne
using water/methanol as eluents. Yield: 150.1 mg, 26%. 1H NMR
(600 MHz, CDCl3) δ: 7.46 (d, 1H), 7.28 (d, J = 8.4 Hz, 1H), 6.88 (d,
Scheme 10b
aCalculated yield for the last step of the reaction. bReaction conditions: (i) tert-butyl 3-bromoazetidine-1-carboxylate, NaH, DMF, 153 °C, 16 h;
(ii) TFA, DCM, rt, 16 h; (iii) heteroaryl chloride, NaH, DMF, 153 °C, 4−16 h or 2-chloroacetyl chloride, Et3N, DCM, 0 °C, 30 min followed by
2,6-dione derivative, K2CO3, 100 °C, 3−16 h.
Figure 4. Scheme of the general structure and the parts that have
been modified.
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Table 1. Synthesized Analogues of Compound 1 and Their Evaluation against T.brucei, MRC5, TbrPDEB1, and hPDE4
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Table 1. continued
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J = 8.4 Hz, 1H), 5.82−5.76 (m, 1H), 5.68 (d, J = 9.4 Hz, 1H), 4.93−
4.84 (m, 1H), 4.71−4.56 (m, 3H), 3.97 (s, 3H), 3.96−3.86 (m, 4H),
3.36−3.31 (m, 1H), 3.31−3.20 (m, 1H), 3.00 (d, J = 18.0 Hz, 1H),
2.80−2.68 (m, 2H), 2.56 (s, 4H), 2.27−2.07 (m, 3H), 2.08−1.66 (m,
4H), 1.19 (s, 6H). 13C NMR (150 MHz, CDCl3) δ: 172.0, 167.0,
167.0, 164.9, 154.6, 154.4, 151.0, 149.5, 127.7, 127.6, 126.2, 126.0,
124.1, 124.0, 119.4, 119.3, 110.7, 108.4, 108.3, 56.3, 56.3, 56.1, 52.3,
46.2, 44.3, 42.0, 40.5, 34.9, 34.8, 31.2, 31.1, 30.5, 29.7, 29.6, 27.9,
23.5, 23.4, 22.5. UPLC: purity >99%. m/z (ES) 551.3 [M + 1].
HRMS: calcd 550.2870; found 551.2861.
Table 1. continued
aEach value is the mean of at least two independent determinations. bCytotoxicity measurement using human lung fibroblast MRC-5 SV2 cells.
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1(2H)-one (2). Reagents: (4aS,8aR)-4-(3,4-dimethoxyphenyl)-2-(pi-
peridin-4-yl)-4a,5,8,8a-tetrahydrophthalazin-1(2H)-one (800 mg, 2.2
mmol), K2CO3 (449 mg, 3.3 mmol), triethylamine (0.4 mL, 2.8
mmol), 7-chlorothieno[3,2-d]pyrimidine (443 mg, 2.60 mmol), and
DMF (8 mL). Reaction conditions: 30 min at 120 °C before the alkyl
reagent and 1 h at 120 °C after the addition of the agent. Purification:
IsoleraOne using water/methanol as eluents. Yield: 756.6 mg, 69%.
1H NMR (600 MHz, CDCl3) δ: 8.59 (s, 1H), 7.75 (d, J = 5.6 Hz,
1H), 7.48 (d, J = 5.6 Hz, 1H), 7.32 (d, J = 2.0 Hz, 1H), 7.24 (dd, J =
8.4, 2.0 Hz, 1H), 6.83 (d, J = 8.4 Hz, 1H), 5.83−5.78 (m, 1H), 5.71−
5.66 (m, 1H), 5.07−4.97 (m, 2H), 4.96−4.90 (m, 1H), 3.89 (s, 3H),
3.76 (s, 3H), 3.36−3.25 (m, 3H), 3.02 (d, J = 16.0 Hz, 1H), 2.78 (t, J
= 5.9 Hz, 1H), 2.32−2.14 (m, 3H), 2.07−1.96 (m, 3H), 1.92−1.86
(m, 1H). 13C NMR (150 MHz, CDCl3) δ: 166.9, 157.9, 154.3, 153.7,
Figure 5. (A) Mouse microsomal stability of selected compounds. (B) Human microsomal stability of selected compounds.
Figure 6. Structures of the compounds studied by X-ray.
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150.9, 149.2, 131.7, 127.5, 126.0, 124.9, 123.9, 119.2, 114.4, 110.6,
108.2, 56.0, 55.8, 52.2, 45.9, 34.8, 31.1, 30.0, 29.3, 23.3, 22.3. UPLC:





4a,5,8,8a-tetrahydrophthalazin-1(2H)-one hydrochloride (350 mg,
0.9 mmol), K2CO3 (154.5 mg, 1.1 mmol), triethylamine (0.4 mL,
2.6 mmol), 6-chloro-9H-purin-2-amine (145.8 mg, 0.9 mmol), and
DMF (2 mL). Reaction conditions: 1 h at 153 °C before the alkyl
reagent and 16 h at 153 °C after the addition of the agent.
Purification: IsoleraOne using water/methanol as eluents. Yield: 66.1
mg, 15%. 1H NMR (400 MHz, MeOD-d4) δ: 7.68 (s, 1H), 7.38 (d, J
= 2.0 Hz, 1H), 7.33 (dd, J = 8.5, 2.1 Hz, 1H), 6.94 (d, J = 8.5 Hz,
1H), 5.83−5.63 (m, 2H), 5.47−5.34 (m, 2H), 5.00−4.91 (m, 1H),
3.83 (s, 3H), 3.66 (s, 3H), 3.52−3.41 (m, 1H), 3.14 (td, J = 13.2, 5.8
Hz, 2H), 2.89 (d, J = 18.1 Hz, 1H), 2.82 (t, J = 5.9 Hz, 1H), 2.37−
2.09 (m, 4H), 2.07−1.67 (m, 5H). 13C NMR (100 MHz, MeOD-d4)
δ: 169.0, 161.3, 156.6, 155.7, 154.3, 152.4, 150.5, 136.5, 128.8, 126.9,
125.1, 120.8, 115.4, 112.1, 109.6, 56.3, 56.2, 54.2, 45.9, 36.0, 31.9,
30.8, 30.2 (2C), 24.2, 23.3. UPLC: purity >99%. m/z (ES) 503.3 [M




4a,5,8,8a-tetrahydrophthalazin-1(2H)-one hydrochloride (300 mg,
0.7 mmol), triethylamine (0.3 mL, 2.2 mmol), potassium carbonate
(132.7 mg, 0.9 mmol), 2-chloroquinazolin-4-amine (132.1 mg, 0.7
mmol), and DMF (3 mL). Reaction conditions: 1 h at 153 °C before
the alkyl reagent and 4 h at 153 °C after the addition of the agent.
Purification: IsoleraOne using hexane/ethyl acetate as eluents. Yield:
96.4 mg, 26%. 1H NMR (400 MHz, CDCl3) δ: 7.55 (d, J = 8.1 Hz,
1H), 7.53−7.45 (m, 2H), 7.36 (d, J = 2.0 Hz, 1H), 7.21 (dd, J = 8.5,
2.0 Hz, 1H), 7.02 (ddd, J = 8.1, 6.0, 2.1 Hz, 1H), 6.79 (d, J = 8.5 Hz,
1H), 5.85−5.52 (m, 4H), 5.07−4.83 (m, 3H), 3.85 (s, 3H), 3.69 (s,
3H), 3.29 (dt, J = 11.5, 5.8 Hz, 1H), 3.10−2.83 (m, 3H), 2.75 (t, J =
5.8 Hz, 1H), 2.25−1.66 (m, 7H). 13C NMR (100 MHz, CDCl3) δ:
166.8, 161.8, 158.8, 153.9, 152.3, 150.6, 149.1, 133.2, 127.7, 126.0,
125.5, 124.0, 122.1, 121.2, 119.1, 110.4, 109.7, 108.1, 55.9, 55.7, 53.2,
43.7, 43.6, 34.7, 30.9, 29.8, 29.2, 23.3, 22.4. UPLC: purity >99%. m/z
(ES) 513 [M + 1]. HRMS: calcd 512.25; found 513.2623 [M + 1].
(4aS,8aR)-2-(1-(4-Aminothieno[3,2-d]pyrimidin-2-yl)piperidin-4-
yl)-4-(3,4-dimethoxyphenyl)-4a,5,8,8a-tetrahydrophthalazin-
1(2H)-one (5). Reagents: (4aS,8aR)-4-(3,4-dimethoxyphenyl)-2-(pi-
peridin-4-yl)-4a,5,8,8a-tetrahydrophthalazin-1(2H)-one hydrochlor-
ide (350 mg, 0.9 mmol), triethylamine (0.4 mL, 2.6 mmol),
potassium carbonate (154.5 mg, 1.1 mmol), 2-chlorothieno[3,2-
d]pyrimidin-4-amine (159.9 mg, 0.9 mmol), and DMF (3 mL).
Reaction conditions: 1 h at 153 °C before the alkyl reagent and 18 h
at 153 °C after the addition of the agent. Purification: IsoleraOne
using hexane (0.5% triethylamine)/ethyl acetate (0.5% triethylamine)
as eluents. Yield: 42.8 mg, 5%. 1H NMR (400 MHz, CDCl3) δ: 7.64
(d, J = 5.1 Hz, 1H), 7.36 (d, J = 1.8 Hz, 1H), 7.29−7.23 (m, 2H),
6.85 (d, J = 8.5 Hz, 1H), 5.88−5.64 (m, 2H), 5.08−4.87 (m, 3H),
3.89 (s, 3H), 3.83 (s, 3H), 3.31 (dt, J = 11.5, 5.8 Hz, 1H), 3.14 (d, J =
11.5 Hz, 2H), 3.06−2.94 (m, 1H), 2.79 (t, J = 5.8 Hz, 1H), 2.33−2.11
(m, 3H), 2.11−1.78 (m, 4H). 13C NMR (100 MHz, CDCl3) δ: 167.1,
158.4, 154.7, 150.9, 149.3, 134.8, 127.7, 126.1, 124.1, 120.7, 119.4,
110.7, 108.6, 107.0, 56.2, 56.1, 52.6, 45.3, 34.9, 31.4, 29.8, 29.1, 23.4,
22.5. UPLC: purity >99%. m/z (ES) 519 [M + 1]. HRMS: calcd




4a,5,8,8a-tetrahydrophthalazin-1(2H)-one hydrochloride (250 mg,
0.6 mmol), triethylamine (0.3 mL, 2.2 mmol), potassium carbonate
(109 mg, 0.7 mmol), 2-chloroquinazoline (108 mg, 0.6 mmol), and
Figure 7. Crystal structures of TbrPDEB1 in complex with selected inhibitors: compound 1 (A), compound 11 (B), compound 12 (C), compound
14 (D), and compound 35 (E). The inhibitors are shown in orange sticks. The P-pocket formed by residues Ala837, Thr841, Tyr845, Asn867,
Met868, Glu869, and Leu870 is represented as surface. Key residues involved in hydrophobic interactions, including the hydrophobic clamp
residues Phe877 and Val840, are shown in yellow lines. Conserved Gln874 is shown in green stick. The two metal ions magnesium and zinc of the
catalytic center are shown in magenta and gray spheres, respectively, and the hydrogen bond interactions are indicated by dashed black lines. Helix-
15 and the M-loop are labeled.
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DMF (3 mL). Reaction conditions: 1 h at 153 °C before the alkyl
reagent and 4 h at 153 °C after the addition of the agent. Purification:
IsoleraOne using hexane/ethyl acetate as eluents. Yield: 182.7 mg,
60%. 1H NMR (400 MHz, DMSO-d6) δ: 9.22 (d, J = 0.7 Hz, 1H),
7.84 (dd, J = 8.1, 0.9 Hz, 1H), 7.73 (ddd, J = 8.5, 6.9, 1.5 Hz, 1H),
7.51 (dd, J = 8.4, 0.7 Hz, 1H), 7.38−7.20 (m, 3H), 6.93 (d, J = 8.5
Hz, 1H), 5.79−5.56 (m, 2H), 5.00−4.79 (m, 3H), 3.74 (s, 3H), 3.47
(s, 3H), 3.46−3.39 (m, 1H), 3.16−3.03 (m, 2H), 2.87−2.71 (m, 2H),
2.24−1.64 (m, 7H). 13C NMR (100 MHz, DMSO-d6) δ: 166.3, 162.0,
158.8, 153.7, 151.6, 150.3, 148.6, 134.4, 127.8, 127.2, 125.8, 125.0,
124.1, 122.5, 119.2, 119.1, 111.3, 108.2, 55.5, 54.9, 52.1, 43.3, 33.9,
29.9, 29.2, 28.6, 22.7, 22.0. UPLC: purity >99%. m/z (ES) 498 [M +




4a,5,8,8a-tetrahydrophthalazin-1(2H)-one hydrochloride (300 mg,
0.7 mmol), triethylamine (0.1 mL, 0.9 mmol), potassium carbonate
(122.7 mg, 0.8 mmol), 4-chloroquinazoline (95.7 mg, 0.7 mmol), and
DMF (5 mL). Reaction conditions: 1 h at 153 °C before the alkyl
reagent and 16 h at 153 °C after the addition of the agent.
Purification: IsoleraOne using DCM/methanol as eluents. Yield:
298.3 mg, 81%. 1H NMR (400 MHz, CDCl3) δ: 8.62 (s, 1H), 7.79
(ddd, J = 16.8, 8.4, 0.8 Hz, 2H), 7.61 (ddd, J = 8.3, 6.9, 1.3 Hz, 1H),
7.37 (d, J = 2.0 Hz, 1H), 7.34 (ddd, J = 8.3, 7.0, 1.2 Hz, 1H), 7.21
(dd, J = 8.5, 2.0 Hz, 1H), 6.78 (d, J = 8.5 Hz, 1H), 5.74−5.55 (m,
2H), 4.96−4.86 (m, 1H), 4.39 (dd, J = 17.8, 14.6 Hz, 2H), 3.80 (s,
3H), 3.79 (s, 3H), 3.32−3.11 (m, 3H), 2.99−2.86 (m, 1H), 2.71 (t, J
= 5.8 Hz, 1H), 2.34 (qd, J = 12.6, 4.1 Hz, 1H), 2.19−2.04 (m, 3H),
2.02−1.72 (m, 3H). 13C NMR (100 MHz, CDCl3) δ: 166.6, 164.4,
153.9, 153.7, 151.5, 150.6, 149.0, 132.2, 128.4, 127.4, 125.8, 125.1,
124.8, 123.7, 119.0, 116.5, 110.4, 108.1, 55.7, 55.7, 52.3, 49.1, 49.1,
34.5, 30.8, 29.8, 29.1, 23.1, 22.1. UPLC: purity >99%. m/z (ES) 498




4a,5,8,8a-tetrahydrophthalazin-1(2H)-one hydrochloride (300 mg,
0.7 mmol), triethylamine (0.1 mL, 0.9 mmol), potassium carbonate
(122.7 mg, 0.8 mmol), 4-chloropyrimidin-2-amine (95.7 mg, 0.7
mmol), and DMF (5 mL). Reaction conditions: 1 h at 153 °C before
the alkyl reagent and 3 h at 153 °C after the addition of the agent.
Purification: IsoleraOne using DCM/methanol as eluents. Yield: 164
mg, 48%. 1H NMR (400 MHz, CDCl3) δ: 7.84 (d, J = 6.2 Hz, 1H),
7.37 (d, J = 2.0 Hz, 1H), 7.30−7.22 (m, 1H), 6.85 (d, J = 8.5 Hz,
1H), 5.98 (d, J = 6.2 Hz, 1H), 5.83−5.62 (m, 2H), 4.97−4.80 (m,
3H), 4.45 (t, J = 15.5 Hz, 2H), 3.89 (s, 3H), 3.85 (s, 3H), 3.31 (dt, J
= 11.6, 5.8 Hz, 1H), 3.05−2.84 (m, 3H), 2.76 (t, J = 5.8 Hz, 1H),
2.27−1.67 (m, 7H). 13C NMR (100 MHz, CDCl3) δ: 166.9, 162.6,
162.5, 156.32, 154.1, 150.9, 149.3, 127.6, 126.0, 124.0, 119.2, 110.6,
108.3, 94.4, 56.0, 55.9, 52.6, 43.5, 43.4, 34.8, 31.04, 29.48, 28.81,
23.34, 22.39. UPLC: purity >99%. m/z (ES) 463 [M + 1]. HRMS:




4a,5,8,8a-tetrahydrophthalazin-1(2H)-one hydrochloride (300 mg,
0.7 mmol), triethylamine (0.1 mL, 0.9 mmol), potassium carbonate
(122.7 mg, 0.8 mmol), 4-chloropyrimidin-2-amine (95.7 mg, 0.7
mmol), and DMF (5 mL). Reaction conditions: 1 h at 153 °C before
the alkyl reagent and 16 h at 153 °C after the addition of the agent.
Purification: IsoleraOne using DCM/methanol as eluents. Yield:
123.4 mg, 36%. 1H NMR (400 MHz, CDCl3) δ: 7.90 (d, J = 5.6 Hz,
1H), 7.40 (d, J = 2.0 Hz, 1H), 7.23 (dd, J = 8.5, 2.0 Hz, 1H), 6.83 (d,
J = 8.5 Hz, 1H), 5.72 (d, J = 5.6 Hz, 1H), 5.81−5.63 (m, 2H), 4.92−
4.67 (m, 5H), 3.88 (s, 3H), 3.84 (s, 3H), 3.29 (dt, J = 11.6, 5.8 Hz,
1H), 3.04−2.82 (m, 3H), 2.75 (t, J = 5.8 Hz, 1H), 2.30−2.04 (m,
4H), 1.94−1.77 (m, 2H), 1.73−1.63 (m, 1H). 13C NMR (100 MHz,
CDCl3) δ: 166.8, 163.4, 161.8, 156.7, 153.9, 150.3, 149.2, 127.8,
126.0, 124.0, 119.1, 110.5, 108.3, 94.6, 56.0, 55.9, 53.2, 43.4, 43.3,
34.8, 31.0, 29.8, 29.1, 23.3, 22.4. UPLC: purity >99%. m/z (ES) 463
[M + 1]. HRMS: calcd 462.24; found 463.2477 [M + 1].
(4aS,8aR)-4-(3,4-Dimethoxyphenyl)-2-(1-(thieno[3,2-d]-
pyrimidin-2-yl)piperidin-4-yl)-4a,5,8,8a-tetrahydrophthalazin-
1(2H)-one (10). Reagents: (4aS,8aR)-4-(3,4-dimethoxyphenyl)-2-
(piperidin-4-yl)-4a,5,8,8a-tetrahydrophthalazin-1(2H)-one hydro-
chloride (200 mg, 0.5 mmol), triethylamine (0.2 mL, 1.5 mmol),
potassium carbonate (89 mg, 0.6 mmol), 2-chlorothieno[3,2-
d]pyrimidine (84 mg, 0.5 mmol), and DMF (1 mL). Reaction
conditions: 1 h at 153 °C before the alkyl reagent and 16 h at 153 °C
after the addition of the agent. Purification: IsoleraOne using water/
methanol as eluents. Yield: 170.5 mg, 69%. 1H NMR (400 MHz,
CDCl3) δ: 8.85 (s, 1H), 7.83 (d, J = 5.4 Hz, 1H), 7.39 (d, J = 2.0 Hz,
1H), 7.25 (dd, J = 8.5, 2.1 Hz, 1H), 6.84 (d, J = 8.5 Hz, 1H), 5.94−
5.58 (m, 2H), 5.15−4.83 (m, 3H), 3.89 (s, 3H), 3.76 (s, 3H), 3.32
(dt, J = 11.6, 5.8 Hz, 1H), 3.14−2.97 (m, 3H), 2.79 (t, J = 5.9 Hz,
1H), 2.31−2.13 (m, 3H), 2.13−1.76 (m, 5H). 13C NMR (100 MHz,
CDCl3) δ: 166.9, 163.5, 160.0, 158.8, 154.0, 152.5, 150.9, 149.3,
127.9, 126.1, 124.1, 123.2, 120.4, 119.2, 110.6, 108.4, 56.1, 55.9, 53.1,
44.4, 44.3, 34.9, 31.2, 29.9, 29.2, 23.5, 22.5. UPLC: purity >99%. m/z
(ES) 504.3 [M + 1]. HRMS: calcd 503.20; found 504.2086 [M + 1].
(4aS,8aR)-2-(1-(2-Aminothieno[2,3-d]pyrimidin-4-yl)piperidin-4-
yl)-4-(3,4-dimethoxyphenyl)-4a,5,8,8a-tetrahydrophthalazin-
1(2H)-one (11). Reagents: (4aS,8aR)-4-(3,4-dimethoxyphenyl)-2-
(piperidin-4-yl)-4a,5,8,8a-tetrahydrophthalazin-1(2H)-one hydro-
chloride (400 mg, 1.0 mmol), triethylamine (0.2 mL, 1.5 mmol),
potassium carbonate (177 mg, 1.2 mmol), 4-chlorothieno[2,3-
d]pyrimidin-2-amine (183 mg, 0.985 mmol), and DMF (2 mL).
Reaction conditions: 1 h at 153 °C before the alkyl reagent and 3 h at
153 °C after the addition of the agent. Purification: IsoleraOne using
water/methanol as eluents. Yield: 243.4 mg, 48%. 1H NMR (400
MHz, CDCl3) δ: 7.38 (d, J = 2.0 Hz, 1H), 7.25 (dd, J = 8.5, 2.1 Hz,
1H), 7.18 (d, J = 6.1 Hz, 1H), 6.87−6.81 (m, 2H), 5.84−5.64 (m,
2H), 4.97 (tt, J = 11.4, 4.3 Hz, 1H), 4.83 (s, 2H), 4.72−4.58 (m, 2H),
3.89 (s, 3H), 3.82 (s, 3H), 3.32 (dt, J = 5.8, 4.1 Hz, 1H), 3.18 (dtd, J
= 15.6, 13.2, 2.6 Hz, 2H), 3.01 (dd, J = 17.7, 2.6 Hz, 1H), 2.78 (t, J =
5.8 Hz, 1H), 2.33−1.71 (m, 7H). 13C NMR (100 MHz, CDCl3) δ:
171.8, 166.2, 159.0, 159.5, 154.2, 150.9, 149.3, 127.6, 126.0, 123.9,
120.9, 119.2, 116.1, 110.6, 110.4, 108.3, 56.0, 55.6, 52.6, 46.5, 34.8,
31.1, 29.9, 29.3, 23.4, 22.4. UPLC: purity >99% m/z (ES) 519.2 [M +




4a,5,8,8a-tetrahydrophthalazin-1(2H)-one hydrochloride (320 mg,
0.8 mmol), potassium carbonate (142 mg, 1.0 mmol), triethylamine
(0.16 mL, 1.2 mmol), 4-chloroquinazolin-2-amine (141.5 mg, 0.8
mmol), and DMF anhydrous (3 mL). Reaction conditions: 1 h at 153
°C before the alkyl reagent and 2 h at 153 °C after the addition of the
agent. Purification: IsoleraOne using heptane/ethyl acetate followed
by a second purification by IsoleraOne using DCM/methanol as
eluents. Yield: 100 mg, 25%. 1H NMR (400 MHz, CDCl3) δ: 7.76 (d,
J = 8.1 Hz, 1H), 7.65−7.53 (m, 2H), 7.43 (d, J = 2.0 Hz, 1H), 7.32
(dd, J = 8.4, 2.0 Hz, 1H), 7.19 (ddd, J = 8.2, 6.6, 1.5 Hz, 1H), 6.90 (d,
J = 8.5 Hz, 1H), 5.90−5.65 (m, 3H), 5.07−4.95 (m, 1H), 4.61−4.46
(m, 2H), 3.93 (s, 3H), 3.92 (s, 3H), 3.41−3.21 (m, 4H), 3.09−2.98
(m, 1H), 2.81 (t, J = 5.5 Hz, 1H), 2.38 (ddd, J = 16.9, 13.6, 5.0 Hz,
1H), 2.31−2.13 (m, 4H), 2.03−1.82 (m, 2H). 13C NMR (100 MHz,
CDCl3) δ: 167.0, 166.1, 158.3, 154.4, 151.0, 149.4, 133.3, 127.7,
126.1, 125.6, 124.0, 121.8, 119.3, 112.1, 110.8, 108.4, 56.1, 56.1, 52.6,
49.3, 49.3, 34.9, 31.2, 30.1, 29.5, 23.5, 22.5. UPLC: purity >99% m/z
(ES) 513 [M + 1]. HRMS: calcd 512.25; found 513.2614 [M + 1].
1-(2-(4-((4aS,8aR)-4-(3,4-Dimethoxyphenyl)-1-oxo-4a,5,8,8a-tet-
rahydrophthalazin-2(1H)-yl)piperidin-1-yl)-2-oxoethyl)pyrrolidine-
2,5-dione (14). Reagents: (4aS,8aR)-2-(1-(2-chloroacetyl)piperidin-
4-yl)-4-(3,4-dimethoxyphenyl)-4a,5,8,8a-tetrahydrophthalazin-1(2H)-
one (500 mg, 1.1 mmol), pyrrolidine-2,5-dione (178.2 mg, 1.8
mmol), potassium carbonate (495.8 mg, 3.57 mmol), and DMF (10
mL). Reaction conditions: 18 h at rt after the addition of the agent.
Purification: IsoleraOne using hexane/ethyl acetate as eluents. Yield:
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280.63 mg, 50%. 1H NMR (600 MHz, CDCl3) δ: 7.43 (dd, J = 6.1,
1.7 Hz, 1H), 7.32−7.29 (m, 1H), 6.89 (d, J = 8.4 Hz, 1H), 5.84−5.76
(m, 1H), 5.68 (d, J = 7.0 Hz, 1H), 4.88 (tt, J = 10.9, 5.4 Hz, 1H),
4.70−4.59 (m, 1H), 4.42−4.29 (m, 2H), 3.97 (s, 3H), 3.93 (s, 3H),
3.91−3.82 (m, 1H), 3.38−3.31 (m, 1H), 3.32−3.20 (m, 1H), 3.01 (d,
J = 18.5 Hz, 1H), 2.81 (s, 4H), 2.80−2.71 (m, 2H), 2.27−2.08 (m,
3H), 2.08−1.98 (m, 1H), 1.98−1.87 (m, 1H), 1.86−1.69 (m, 2H).
13C NMR (151 MHz, CDCl3) δ: 177.0, 167.1, 167.0, 163.3, 163.3,
154.7, 154.5, 151.1, 151.1, 149.5, 127.6, 127.6, 126.2, 126.0, 124.1,
124.0, 119.4, 119.3, 110.8, 110.7, 108.4, 108.3, 56.4, 56.3, 56.1, 52.2,
44.2, 42.1, 39.8, 39.8, 34.9, 34.8, 31.3, 31.2, 30.4, 29.7, 29.5, 28.9,
28.4, 23.5, 23.4, 22.5. UPLC: purity >99%, m/z (ES) 509.2 [M + 1].
HRMS: calcd 508.2400; found 509.2389 [M + 1].
1-(2-(4-((4aS,8aR)-4-(3,4-Dimethoxyphenyl)-1-oxo-4a,5,8,8a-tet-
rahydrophthalazin-2(1H)-yl)piperidin-1-yl)-2-oxoethyl)-3-methyl-
pyrrolidine-2,5-dione (15). Reagents: (4aS,8aR)-2-(1-(2-
chloroacetyl)piperidin-4-yl)-4-(3,4-dimethoxyphenyl)-4a,5,8,8a-tetra-
hydrophthalazin-1(2H)-one (500 mg, 1.1 mmol), 3-methylpyrroli-
dine-2,5-dione (202.0 mg, 1.8 mmol), potassium carbonate (493 mg,
3.57 mmol), and DMF (10 mL). Reaction conditions: 18 h at rt after
the addition of the agent. Purification: IsoleraOne using hexane/ethyl
acetate as eluents, followed by a second purification by IsoleraOne
using water/methanol as eluents. Yield: 150.1 mg, 26%. 1H NMR
(400 MHz, CDCl3) δ: 7.48−7.40 (m, 1H), 7.31 (dd, J = 8.5, 1.7 Hz,
1H), 6.90 (dd, J = 8.5, 3.7 Hz, 1H), 5.86−5.64 (m, 2H), 4.90 (ddd, J
= 15.6, 7.7, 4.0 Hz, 1H), 4.73−4.57 (m, 1H), 4.43−4.25 (m, 2H),
4.03−3.80 (m, 7H), 3.31 (ddd, J = 38.4, 17.8, 9.6 Hz, 2H), 3.07−2.91
(m, 3H), 2.86−2.69 (m, 2H), 2.44 (t, J = 11.8 Hz, 1H), 2.31−1.59
(m, 7H), 1.40 (t, J = 8.2 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ:
180.4, 176.3, 167.1, 163.4, 154.7, 151.1, 149.5, 127.6, 126.2, 124.1,
119.4, 110.8, 108.4, 56.3, 52.2, 44.2, 42.1, 39.7, 36.6, 35.1, 34.9, 31.3,
30.4, 29.7, 28.9, 23.4, 22.5, 16.9. UPLC: purity >99%, m/z (ES) 523.0
[M + 1]. HRMS: calcd 522.25; found 523.2589 [M + 1].
3-Benzyl-1-(2-(1-((4aS,8aR)-4-(3,4-dimethoxyphenyl)-1-oxo-
4a,5,8,8a-tetrahydrophthalazin-2(1H)-yl)piperidin-4-yl)-2-
oxoethyl)pyrrolidine-2,5-dione (16). Reagents: (4aS,8aR)-2-(4-(2-
chloroacetyl)piperidin-1-yl)-4-(3,4-dimethoxyphenyl)-4a,5,8,8a-tetra-
hydrophthalazin-1(2H)-one (135 mg, 0.3 mmol), 3-benzylpyrroli-
dine-2,5-dione (57 mg, 0.3 mmol), potassium carbonate (84 mg, 0.6
mmol), and DMF (2 mL). Reaction conditions: 18 h at 60 °C after
the addition of the agent. Purification: IsoleraOne using hexane/ethyl
acetate as eluents, followed by a second purification by IsoleraOne
using water/methanol as eluents. Yield: 35 mg, 19%. 1H NMR (400
MHz, CDCl3) δ: 7.45−7.19 (m, 7H), 6.89 (d, J = 8.4 Hz, 1H), 5.81−
5.67 (m, 2H), 4.98−4.60 (m, 4H), 3.95 (s, 3H), 3.94 (s, 3H), 3.79−
3.61 (m, 1H), 3.42−3.09 (m, 3H), 3.09−2.91 (m, 3H), 2.89−2.67
(m, 3H), 2.59 (dd, J = 6.3, 2.7 Hz, 1H), 2.30−1.95 (m, 4H), 1.95−
1.68 (m, 3H). UPLC: purity >99%, m/z (ES) 599.0 [M + 1]. HRMS:
calcd 598.3; found 599.2896 [M + 1].
3-(2-(4-((4aS,8aR)-4-(3,4-Dimethoxyphenyl)-1-oxo-4a,5,8,8a-tet-
rahydrophthalazin-2(1H)-yl)piperidin-1-yl)-2-oxoethyl)-3-azaspiro-
[5.5]undecane-2,4-dione (17). Reagents: (4aS,8aR)-2-(1-(2-
chloroacetyl)piperidin-4-yl)-4-(3,4-dimethoxyphenyl)-4a,5,8,8a-tetra-
hydrophthalazin-1(2H)-one (300 mg, 0.7 mmol), potassium carbo-
nate (296 mg, 2.1 mmol), 3-azaspiro[5.5]undecane-2,4-dione (194
mg, 1.1 mmol), and DMF (2 mL). Reaction conditions: 1 h at 153 °C
after the addition of the agent. Purification: IsoleraOne using water/
methanol as eluents. Yield: 187.7 mg, 47%. 1H NMR (400 MHz,
CDCl3) δ: 7.47 (s, 1H), 7.32−7.28 (m, 1H), 6.89 (d, J = 8.5 Hz, 1H),
5.85−5.65 (m, 2H), 4.95−4.83 (m, 1H), 4.73−4.56 (m, 3H), 3.99 (s,
2H), 3.94 (s, 3H), 3.39−3.18 (m, 2H), 3.07−2.97 (m, 1H), 2.83−
2.69 (m, 2H), 2.63 (s, 4H), 2.31−1.64 (m, 7H), 1.63−1.48 (m, 12H).
13C NMR (100 MHz, CDCl3) δ: 177.9, 167.0, 164.9, 154.5, 150.9,
149.5, 127.7, 126.2, 124.1, 119.3, 110.6, 108.3, 56.2, 52.3, 44.3, 43.9,
42.0, 40.5, 36.2, 36.1, 34.7, 31.1, 30.4, 29.6, 29.0, 25.8, 23.4, 22.5,
21.6. UPLC: purity >99%, m/z (ES) 591.3 [M + 1]. HRMS: calcd
590.30; found 591.3182 [M + 1].
cis-2-(1-(2-Aminothieno[2,3-d]pyrimidin-4-yl)piperidin-4-yl)-4-
(3-chloro-4-methoxyphenyl)-4a,5,8,8a-tetrahydrophthalazin-
1(2H)-one (24). Reagents: cis-4-(3-chloro-4-methoxyphenyl)-2-(pi-
peridin-4-yl)-4a,5,8,8a-tetrahydrophthalazin-1(2H)-one (40.3 mg, 0.1
mmol), potassium carbonate (22.34 mg, 0.162 mmol), 4-chloro-2-
aminothieno[2,3-d]pyrimidine (20 mg, 0.1 mmol), and DMF (3 mL).
Reaction conditions: 1 h at 120 °C without the alkyl agent and 16 h at
120 °C after the addition of the agent. Purification: IsoleraOne using
heptane/ethyl acetate as eluents, followed by a second purification by
IsoleraOne using water/methanol as eluents. Yield: 45 mg, 80%. 1H
NMR (400 MHz, CDCl3) δ: 7.77 (d, J = 2.2 Hz, 1H), 7.66 (dd, J =
8.7, 2.3 Hz, 1H), 7.20 (d, J = 6.1 Hz, 1H), 6.94 (d, J = 8.7 Hz, 1H),
6.87 (d, J = 6.1 Hz, 1H), 5.84−5.64 (m, 2H), 5.01−4.91 (m, 1H),
4.86 (s, 2H), 4.76−4.61 (m, 2H), 3.93 (s, 3H), 2.25−3.32 (m, 1H),
3.24−3.11 (m, 2H), 3.01 (d, J = 18.0 Hz, 1H), 2.78 (t, J = 5.8 Hz,
1H), 2.29−2.12 (m, 3H), 2.09−1.76 (m, 4H). 13C NMR (100 MHz,
CDCl3) δ: 167.0, 165.8, 158.9, 157.3, 156.4, 153.4, 128.2, 127.8,
126.1, 125.7, 123.9, 123.1, 121.2, 117.2, 112.0, 110.6, 56.5, 52.4, 46.7,
46.6, 34.8, 31.2, 30.1, 29.4, 23.2, 22.4. UPLC: purity ≥99% m/z (ES)




drophthalazin-1(2H)-one (176 mg, 0.5 mmol), potassium carbonate
(112 mg, 0.8 mmol), 4-chloro-2-aminothieno[2,3-d]pyrimidine (100
mg, 0.5 mmol), and DMF (3 mL). Reaction conditions: 1 h at 120 °C
without the alkyl agent and 16 h at 120 °C after the addition of the
agent. Purification: IsoleraOne using heptane/ethyl acetate as eluents,
followed by a second purification by IsoleraOne using water/
methanol as eluents. Yield: 40 mg, 16%. 1H NMR (400 MHz,
DMSO-d6) δ: 7.93−7.85 (m, 2H), 7.32 (d, J = 6.2 Hz, 1H), 7.28−
7.21 (m, 2H), 7.01 (d, J = 6.1 Hz, 1H), 6.22 (s, 2H), 5.60−5.76 (m,
2H), 4.78−4.88 (m, 1H), 4.52−4.65 (m, 2H), 3.43−3.50 (m, 1H),
3.20−3.09 (m, 2H), 2.90 (t, J = 5.8 Hz, 1H), 2.76 (d, J = 17.8 Hz,
1H), 2.24−1.98 (m, 3H), 1.92−1.69 (m, 4H). 13C NMR (100 MHz,
DMSO-d6) δ: 171.7, 166.5, 162.96 (d, J = 247.4 Hz), 159.9, 158.8,
153.2, 131.20 (d, J = 3.0 Hz), 128.20 (d, J = 8.6 Hz), 125.8, 124.0,
121.4, 115.70 (d, J = 21.6 Hz), 114.9, 108.6, 52.0, 45.2, 33.8, 30.0,
29.8, 29.6, 22.4, 21.9. UPLC: purity >99%, m/z (ES) 477 [M + 1].




tetrahydrophthalazin-1(2H)-one (130 mg, 0.4 mmol), potassium
carbonate (78 mg, 0.6 mmol), 4-chloro-2-aminothieno[2,3-d]-
pyrimidine (70 mg, 0.4 mmol), and DMF (3 mL). Reaction
conditions: 1 h at 120 °C without the alkyl agent and 4 h at 120
°C after the addition of the agent. Purification: IsoleraOne using
heptane/ethyl acetate as eluents, followed by a second purification by
IsoleraOne using water/methanol as eluents. Yield: 60 mg, 32%. 1H
NMR (400 MHz, CDCl3) δ: 7.58−7.66 (m, 1H), 7.52−7.45 (m, 1H),
7.23−7.14 (m, 2H), 6.88 (d, J = 6.1 Hz, 1H), 5.84−5.64 (m, 2H),
5.02−4.89 (m, 1H), 4.83 (s, 2H), 4.75−4.62 (m, 2H), 3.24−3.31 (m,
1H), 3.10−3.23 (m, 2H), 2.97−3.07 (m, 1H), 2.80 (t, J = 5.9 Hz,
1H), 2.29−2.13 (m, 3H), 2.10−1.78 (m, 4H). 13C NMR (100 MHz,
CDCl3) δ: 168.4, 166.9, 159.2, 158.2, 152.5 (t, J = 2.1 Hz), 151.5 (dd,
J = 252.8, 12.8 Hz), 150.7 (dd, J = 248.9, 12.9 Hz), 132.0 (dd, J = 5.6,
3.7 Hz), 126.1, 123.7, 122.2 (dd, J = 6.5, 3.5 Hz), 121.0, 117.7 (d, J =
17.7 Hz), 116.9, 114.9 (d, J = 18.6 Hz), 110.6, 52.7, 46.6, 46.5, 34.8,
31.3, 30.2, 29.5, 23.1, 22.3. UPLC: purity >99%, m/z (ES) 495.2 [M




4a,5,8,8a-tetrahydrophthalazin-1(2H)-one (300 mg, 0.9 mmol),
potassium carbonate (180 mg, 1.3 mmol), triethylamine (114 mg,
1.1 mmol), 7-chlorothieno[3,2-d]pyrimidine (148.3 mg, 0.9 mmol),
and DMF (2 mL). Reaction conditions: 30 min at 120 °C without the
alkyl agent and 3 h at 120 °C after the addition of the agent.
Purification: IsoleraOne using heptane/ethyl acetate as eluents,
followed by a second purification by IsoleraOne using water/
methanol as eluents. Yield: 90.8 mg, 22%. 1H NMR (400 MHz,
CDCl3) δ: 8.62 (s, 1H), 7.77 (dd, J = 10.4, 5.6 Hz, 1H), 7.60 (ddd, J
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= 11.6, 7.6, 2.2 Hz, 1H), 7.54 (d, J = 5.5 Hz, 1H), 7.47 (ddd, J = 8.7,
4.1, 1.6 Hz, 1H), 7.18 (dt, J = 9.7, 8.4 Hz, 1H), 5.88−5.64 (m, 2H),
5.12−4.92 (m, 3H), 3.41−3.20 (m, 3H), 3.02 (dd, J = 13.3, 7.1 Hz,
1H), 2.81 (t, J = 5.8 Hz, 1H), 2.32−2.13 (m, 3H), 2.12−1.84 (m,
4H). 13C NMR (100 MHz, CDCl3) δ: 166.9, 160.7, 157.9, 153.7,
152.5, 150.7 (d, J = 236.5 Hz), 131.9, 126.1, 125.0, 123.7, 122.2 (dd, J
= 6.4, 3.5 Hz), 117.7 (d, J = 17.8 Hz), 114.9 (d, J = 18.5 Hz), 114.4,
52.7, 45.8, 45.7, 34.8, 31.3, 30.4, 29.6, 23.6, 22.3. UPLC: purity >99%,




dine-2,6-dione (28). Reagents: cis-2-(1-(2-chloroacetyl)piperidin-4-
yl)-4-(4-fluorophenyl)-4a,5,8,8a-tetrahydrophthalazin-1(2H)-one
(200 mg, 0.5 mmol), potassium carbonate (205 mg, 1.5 mmol), 4,4-
dimethylpiperidine-2,6-dione (105 mg, 0.7 mmol), and DMF (3 mL).
Reaction conditions: 3 h at 100 °C after the addition of the agent.
Purification: IsoleraOne using heptane/ethyl acetate as eluents. Yield:
65 mg, 26%. 1H NMR (400 MHz, CDCl3) δ: 7.80−7.72 (m, 2H),
7.09−7.01 (m, 2H), 5.81−5.53 (m, 2H), 4.88−4.73 (m, 1H), 4.71−
4.49 (m, 3H), 3.94−3.75 (m, 1H), 3.35−3.09 (m, 2H), 3.02−2.87
(m, 1H), 2.78−2.58 (m, 2H), 2.52 (s, 4H), 2.24−1.59 (m, 7H), 1.13
(s, 6H). 13C NMR (100 MHz, CDCl3) δ: 172.4, 167.0, 164.8, 163.9
(d, J = 250.7 Hz), 153.6, 130.9, 128.0 (dd, J = 8.1 Hz), 126.1, 123.9,
115.9 (d, J = 21.8 Hz), 77.2, 52.3, 46.2, 44.2, 41.8, 40.6, 34.9, 31.3,
30.4, 29.6, 29.5, 28.9, 27.9, 23.2, 22.4. UPLC: purity >99%, m/z (ES)
509.4 [M + 1]. HRMS: calcd 508.25.; found 509.2587 [M + 1].
cis-3-(2-(4-(4-(4-Fluorophenyl)-1-oxo-4a,5,8,8a-tetrahydroph-
thalazin-2(1H)-yl)piperidin-1-yl)-2-oxoethyl)-3-azaspiro[5.5]-
undecane-2,4-dione (29). Reagents: cis-2-(1-(2-chloroacetyl)-
piperidin-4-yl)-4-(4-fluorophenyl)-4a,5,8,8a-tetrahydrophthalazin-
1(2H)-one (200 mg, 0.5 mmol), potassium carbonate (205 mg, 1.5
mmol), 3-azaspiro[5.5]undecane-2,4-dione (135 mg, 0.7 mmol), and
DMF (3 mL). Reaction conditions: 3 h at 100 °C after the addition of
the agent. Purification: IsoleraOne using water/methanol as eluents.
Yield: 70 mg, 26%. 1H NMR (400 MHz, CDCl3) δ: 7.86−7.80 (m,
2H), 7.17−7.08 (m, 2H), 5.86−5.61 (m, 2H), 4.97−4.47 (m, 5H),
4.01−3.81 (m, 1H), 3.29 (m, 2H), 3.00 (d, J = 18.2 Hz, 1H), 2.84−
2.57 (m, 6H), 2.31−1.36 (m, 16H). 13C NMR (100 MHz, CDCl3) δ:
172.1, 166.9, 164.8, 163.9 (d, J = 250.6 Hz), 153.5, 130.9, 128.0 (d, J
= 8.4 Hz), 126.1, 123.9, 115.9 (d, J = 21.8 Hz), 52.3, 43.9, 41.8, 40.5,
36.2, 34.8, 32.1, 31.3, 29.0, 25.9, 25.8, 23.1, 22.4, 21.7. UPLC: purity
>99%, m/z (ES) 549.5 [M + 1]. HRMS: calcd 548.28; found
549.2877 [M + 1].
cis-8-(2-(4-(4-(4-Fluorophenyl)-1-oxo-4a,5,8,8a-tetrahydroph-
thalazin-2(1H)-yl)piperidin-1-yl)-2-oxoethyl)-8-azaspiro[4.5]-
decane-7,9-dione (30). Reagents: cis-2-(1-(2-chloroacetyl)piperidin-
4-yl)-4-(4-fluorophenyl)-4a,5,8,8a-tetrahydrophthalazin-1(2H)-one
(200 mg, 0.5 mmol), potassium carbonate (205 mg, 1.5 mmol), 8-
azaspiro[4.5]decane-7,9-dione (124 mg, 0.7 mmol), and DMF (3
mL). Reaction conditions: 3 h at 100 °C after the addition of the
agent. Purification: IsoleraOne using heptane/ethyl acetate as eluents.
Yield: 60 mg, 23%. 1H NMR (400 MHz, CDCl3) δ: 7.79−7.73 (m,
2H), 7.09−7.01 (m, 2H), 5.78−5.55 (m, 2H), 4.81 (tt, J = 11.4, 3.9
Hz, 1H), 4.69−4.44 (m, 3H), 3.95−3.74 (m, 1H), 3.33−3.08 (m,
2H), 2.94 (d, J = 18.3 Hz, 1H), 2.76−2.48 (m, 6H), 2.23−1.36 (m,
15H). 13C NMR (100 MHz, CDCl3) δ: 172.4, 167.0, 164.8, 163.9 (d,
J = 250.7 Hz), 153.6, 130.9, 128.0 (dd, J = 8.1 Hz), 126.1, 123.9,
115.9 (d, J = 21.8 Hz), 77.2, 52.3, 44.5, 44.2, 41.8, 40.6, 39.7, 37.8,
34.9, 31.3, 30.4, 29.6, 28.9, 24.2, 23.2, 22.4. UPLC: purity >99%, m/z
(ES) 535.6 [M + 1]. HRMS: calcd 534.26; found 535.2721 [M + 1].
cis-3-(2-(4-(4-(3,4-Difluorophenyl)-1-oxo-4a,5,8,8a-tetrahy-
drophthalazin-2(1H)-yl)piperidin-1-yl)-2-oxoethyl)-3-azaspiro[5.5]-
undecane-2,4-dione (31). Reagents: cis-2-(1-(2-chloroacetyl)-
piperidin-4-yl)-4-(3,4-difluorophenyl)-4a,5,8,8a-tetrahydrophthalazin-
1(2H)-one (169.3 mg, 0.4 mmol), 3,3-pentamethyleneglutarimide
(87 mg, 0.5 mmol), potassium carbonate (222 mg, 1.6 mmol), and
DMF (5 mL). Reaction conditions: 1 h at 120 °C after the addition of
the agent. Purification: IsoleraOne using heptane/ethyl acetate as
eluents. Yield: 99.3 mg, 44%. 1H NMR (400 MHz, CDCl3) δ: 7.76−
7.66 (m, 1H), 7.61−7.54 (m, 1H), 7.30−7.20 (m, 1H), 5.89−5.64
(m, 2H), 4.94−4.86 (m, 1H), 4.78−4.54 (m, 3H), 4.04−3.86 (m,
1H), 3.37−3.19 (m, 2H), 3.06−3.00 (m, 1H), 2.85−2.60 (m, 6H),
2.32−1.65 (m, 7H), 1.66−1.40 (m, 10H). 13C NMR (100 MHz,
CDCl3) δ 172.1, 166.9, 165.0 (d, J = 4.4 Hz), 132.0, 126.1 (d, J = 12.7
Hz), 123.7 (d, J = 10.4 Hz), 122.3, 117.7 (d, J = 17.8 Hz), 115.1 (dd,
J = 19.8, 2.8 Hz), 52.5, 52.4, 44.3, 43.9, 41.9, 40.5, 40.4, 36.2, 34.8,
34.8, 32.1, 31.2, 31.1, 30.4, 29.6, 28.97, 25.9, 23.2, 23.0, 22.3, 21.7.
UPLC: purity >99%, m/z (ES) 567.3 [M + 1]. HRMS: calcd 566.27;
found 567.2805 [M + 1].
cis-1-(2-(4-(4-(3,4-Difluorophenyl)-1-oxo-4a,5,8,8a-tetrahy-
drophthalazin-2(1H)-yl)piperidin-1-yl)-2-oxoethyl)-4,4-dimethylpi-
peridine-2,6-dione (32). Reagents: cis-2-(1-(2-chloroacetyl)piperidin-
4-yl)-4-(3,4-difluorophenyl)-4a,5,8,8a-tetrahydrophthalazin-1(2H)-
one (400 mg, 0.9 mmol), 4,4-dimethylpiperidine-2,6-dione (161 mg,
1.1 mmol), potassium carbonate (524 mg, 3.8 mmol), and DMF (5
mL). Reaction conditions: 16 h at 120 °C after the addition of the
agent. Purification: IsoleraOne using heptane/ethyl acetate/methanol
as eluents. Yield: 22.6 mg, 5%. 1H NMR (400 MHz, CDCl3) δ: 7.68
(dd, J = 11.3, 7.9 Hz, 1H), 7.55 (ddd, J = 8.7, 4.0, 1.7 Hz, 1H), 7.21
(dt, J = 9.7, 8.5 Hz, 1H), 5.83−5.62 (m, 2H), 4.96−4.79 (m, 1H),
4.76−4.51 (m, 3H), 3.91 (t, J = 16.5 Hz, 1H), 3.35−3.14 (m, 2H),
2.99 (d, J = 18.0 Hz, 1H), 2.84−2.62 (m, 2H), 2.58 (s, 4H), 2.29−
1.61 (m, 7H), 1.19 (s, 6H). 13C NMR (100 MHz, CDCl3) δ: 172.1,
166.9, 165.0, 152.3 (dd, J = 78.9, 12.8 Hz), 149.8 (dd, J = 75.2, 12.8
Hz), 131.9 (d, J = 4.0 Hz), 126.1, 123.8, 122.3 (d, J = 3.7 Hz), 117.6
(d, J = 17.6 Hz), 115.1 (d, J = 16.5 Hz), 53.6, 52.4, 52.4, 46.2, 41.9,
40.4, 34.8, 34.7, 31.2, 31.1, 30.4, 29.5, 29.0, 27.9, 23.1, 23.0, 22.3.
UPLC: purity >99%, m/z (ES) 527.2 [M + 1]. HRMS: calcd 526.24;
found 527.2470 [M + 1].
1-(2-(4-((4aS,8aR)-4-(3,4-Bis(difluoromethoxy)phenyl)-1-oxo-
4a,5,8,8a-tetrahydrophthalazin-2(1H)-yl)piperidin-1-yl)-2-oxoeth-
yl)-4,4-dimethylpiperidine-2,6-dione (35). Reagents: (4aS,8aR)-4-
(3,4-bis(difluoromethoxy)phenyl)-2-(1-(2-chloroacetyl)piperidin-4-
yl)-4a,5,8,8a-tetrahydrophthalazin-1(2H)-one (170 mg, 0.3 mmol),
3,3-dimethylglutarimide (93 mg, 0.7 mmol), potassium carbonate
(181 mg, 1.3 mmol), and DMF (2 mL). Reaction conditions: 16 h at
120 °C after the addition of the agent. Purification: IsoleraOne using
heptane/ethyl acetate as eluents. Yield: 20 mg, 10%. 1H NMR (400
MHz, CDCl3) δ: 7.72 (dt, J = 6.5, 3.2 Hz, 1H), 7.69 (d, J = 1.9 Hz,
1H), 7.35 (d, J = 8.6 Hz, 1H), 6.72 (t, J = 73.4 Hz, 2H), 6.60 (t, J =
73.2 Hz, 2H), 5.90−5.61 (m, 2H), 4.99−4.84 (m, 1H), 4.66 (s, 2H),
4.07−3.84 (m, 1H), 3.32 (dt, J = 11.6, 6.9 Hz, 1H), 3.03 (d, J = 18.5
Hz, 1H), 2.80 (dd, J = 14.5, 8.8 Hz, 1H), 2.61 (s, 4H), 2.34−1.68 (m,
8H), 1.22 (s, 6H). 13C NMR (100 MHz, CDCl3) δ: 172.1 (2C),
166.9, 165.0, 152.3, 143.4, 142.6, 133.6, 126.1, 124.2, 123.7, 122.3,
119.5, 115.9 (t, J = 263.0 Hz), 115.7 (t, J = 263.0 Hz), 52.4, 46.2
(2C), 44.3, 42.0, 40.4, 34.8, 32.0, 31.2, 29.5 (2C), 27.9 (2C), 23.1,
22.3. UPLC: purity >99%, m/z (ES) 623.1 [M + 1]. HRMS: calcd
622.24; found 623.2495 [M + 1].
3-(2-(4-((4aS,8aR)-4-(3,4-Bis(difluoromethoxy)phenyl)-1-oxo-
4a,5,8,8a-tetrahydrophthalazin-2(1H)-yl)piperidin-1-yl)-2-oxoeth-
yl)-3-azaspiro[5.5]undecane-2,4-dione (36). Reagents: (4aS,8aR)-4-
(3,4-bis(difluoromethoxy)phenyl)-2-(1-(2-chloroacetyl)piperidin-4-
yl)-4a,5,8,8a-tetrahydrophthalazin-1(2H)-one (243 mg, 0.2 mmol),
potassium carbonate (130 mg, 0.9 mmol), 3,3-pentamethylene-
glutarimide (51.0 mg, 0.3 mmol), and DMF (2 mL). Reaction
conditions: 16 h at 100 °C after the addition of the agent.
Purification: IsoleraOne using heptane/ethyl acetate as eluents.
Yield: 9.7 mg, 6%. 1H NMR (400 MHz, CDCl3) δ: 7.64 (dd, J =
8.6, 2.1 Hz, 1H), 7.59 (s, 1H), 7.26 (d, J = 8.6 Hz, 1H), 6.83−6.29
(m, 2H), 5.81−5.54 (m, 2H), 4.82 (tt, J = 11.4, 4.0 Hz, 1H), 4.69−
4.45 (m, 3H), 3.86 (dd, J = 30.0, 14.1 Hz, 1H), 3.30−3.08 (m, 2H),
2.93 (d, J = 18.4 Hz, 1H), 2.78−2.61 (m, 2H), 2.57 (s, 4H), 2.27−
1.28 (m, 17H). 13C NMR (100 MHz, CDCl3) δ: 171.9, 166.8, 164.8,
152.2, 143.9, 142.5, 133.5, 126.0, 124.1, 123.6, 122.2, 119.5, 115.7 (t,
J = 262.8 Hz), 115.6 (t, J = 262.8 Hz), 52.4, 52.3, 44.2, 43.8, 41.8,
40.4, 40.3, 36.1, 34.7, 32.0, 31.2, 30.3, 29.6, 28.9, 25.8, 23.1, 23.0,
22.2, 21.6. UPLC: purity = 95%, m/z (ES) 663.1 [M + 1]. HRMS:
calcd 662.3; found 663.2806 [M + 1].
Journal of Medicinal Chemistry pubs.acs.org/jmc Article
https://dx.doi.org/10.1021/acs.jmedchem.9b00985





triazin-2-one (100 mg, 0.3 mmol), triethylamine (42.7 mg, 0.4 mmol),
potassium carbonate (50.6 mg, 0.4 mmol), 4-chloro-2-aminothieno-
[2,3-d]pyrimidine (52.2 mg, 0.3 mmol), and DMF (5 mL). Reaction
conditions: 90 min at 130 °C without the alkyl agent and 3 h at 130
°C after adding the agent. Purification: IsoleraOne using water/
methanol. Yield: 29.7 mg, 21%. 1H NMR (400 MHz, CDCl3) δ: 8.07
(s, 1H), 7.99−7.92 (m, 2H), 7.71 (d, J = 1.3 Hz, 1H), 7.31 (d, J = 5.8
Hz, 1H), 7.14 (d, J = 5.9 Hz, 1H), 7.00 (d, J = 8.5 Hz, 1H), 5.34−
5.22 (m, 1H), 5.03−4.91 (m, 2H), 3.97 (s, 3H), 3.95 (s, 3H), 3.60−
3.47 (m, 2H), 2.46−2.15 (m, 4H). 13C NMR (100 MHz, CDCl3) δ:
157.8, 153.7, 151.4, 149.0, 144.3, 138.5, 134.7, 124.7, 121.7, 121.6,
121.3, 119.1, 114.8, 114.3, 111.9, 111.7, 111.2, 110.9, 110.7, 56.3,
56.2, 55.0, 46.8, 30.4. UPLC: purity >99%, m/z (ES) 505 [M + 1].
HRMS: calcd 504.17; found 505.1776 [M + 1].
2-(1-(2-Aminothieno-[2,3-d]pyrimidin-4-yl)piperidin-4-yl)-6-(3,4-
dimethoxyphenyl)pyridazin-3(2H)-one (51). Reagents: 6-(3,4-dime-
thoxyphenyl)-2-(piperidin-4-yl)pyridazin-3(2H)-one (200 mg, 0.6
mmol), triethylamine (0.1 mL, 0.9 mmol), potassium carbonate
(114 mg, 0.8 mmol), 4-chlorothieno[2,3-d]pyrimidin-2-amine (118
mg, 0.6 mmol), and DMF (3 mL). Reaction conditions: 90 min at
130 °C without the alkyl agent and 16 h at 130 °C after adding the
agent. Purification: IsoleraOne using water/methanol and after that a
second purification using hexane/ethyl acetate as eluents. Yield: 31.6
mg, 11%. 1H NMR (400 MHz, MeOD-d4) δ: 7.99 (d, J = 9.3 Hz,
1H), 7.60 (d, J = 4.7 Hz, 1H), 7.42 (s, 2H), 7.34 (d, J = 4.7 Hz, 1H),
7.06 (d, J = 9.3 Hz, 1H), 7.01 (d, J = 8.1 Hz, 1H), 5.38 (s, 2H), 4.97
(s, 3H), 3.86 (s, 3H), 3.83 (s, 3H), 3.59 (s, 2H), 2.21 (s, 4H). 13C
NMR (100 MHz, CDCl3) δ: 159.4, 157.8, 153.6, 150.7, 149.5, 144.8,
130.1, 130.0, 127.5, 121.7, 119.3, 111.5, 110.7, 109.2, 56.7, 56.3, 54.2,
47.1, 30.6. UPLC: purity >99%, m/z (ES) 465 [M + 1]. HRMS: calcd




5(4H)-one 2,2,2-trifluoroacetate (223 mg, 0.5 mmol), sodium hydride
(24 mg, 1 mmol), 4-chlorothieno[3,2-d]pyrimidine (128 mg, 0.75
mmol), and DMF anhydrous (2 mL). Reaction conditions: 1 h at 153
°C before the alkyl reagent and 16 h at 153 °C after the addition of
the agent. Purification: IsoleraOne using hexane/ethyl acetate as
eluents. Yield: 61.4 mg, 26%. 1H NMR (400 MHz, CDCl3) δ: 8.63 (s,
1H), 7.82 (d, J = 5.6 Hz, 1H), 7.59 (d, J = 5.4 Hz, 1H), 7.39 (d, J =
2.0 Hz, 1H), 7.27 (dd, J = 8.4, 2.1 Hz, 1H), 6.86 (d, J = 8.5 Hz, 1H),
5.04 (d, J = 13.7 Hz, 2H), 4.52 (tt, J = 11.3, 4.3 Hz, 1H), 3.92 (s, 3H),
3.91 (s, 3H), 3.36 (t, J = 12.0 Hz, 2H), 2.23 (ddd, J = 16.2, 12.7, 4.1
Hz, 2H), 2.06 (dd, J = 12.7, 2.9 Hz, 2H), 1.51 (s, 6H). 13C NMR
(100 MHz, CDCl3) δ: 178.3, 162.1, 158.8, 157.8, 152.9, 151.0, 149.4,
132.7, 124.4, 123.7, 119.7, 114.4, 110.6, 108.8, 56.2, 56.1, 50.5, 48.9,
45.8, 30.4, 23.1. UPLC: purity ≥99% m/z (ES) 466 [M + 1]. HRMS:
calcd 465.18; found 466.1912 [M + 1].
(4aS,8aR)-2-(1-(2-Aminothieno[2,3-d]pyrimidin-4-yl)azetidin-3-
yl)-4-(3,4-dimethoxyphenyl)-4a,5,8,8a-tetrahydrophthalazin-
1(2H)-one (59). Reagents: (4aS,8aR)-2-(azetidin-3-yl)-4-(3,4-dime-
thoxyphenyl)-4a,5,8,8a-tetrahydrophthalazin-1(2H)-one 2,2,2-trifluor-
oacetate (446 mg, 1.0 mmol), sodium hydride (47 mg, 1.9 mmol), 4-
chlorothieno[2,3-d]pyrimidin-2-amine (218 mg, 1.2 mmol), and
DMF anhydrous (2 mL). Reaction conditions: 1 h at 153 °C without
the alkyl agent and 4 h at 153 °C after the addition of the agent.
Purification: IsoleraOne using heptane/ethyl acetate as eluents,
followed by a second purification by IsoleraOne using water/
methanol as eluents. Yield: 12 mg, 3%. 1H NMR (400 MHz,
CDCl3) δ: 7.36 (d, J = 1.9 Hz, 1H), 7.23 (dd, J = 8.4, 2.0 Hz, 1H),
7.08 (d, J = 6.0 Hz, 1H), 6.85 (d, J = 5.9 Hz, 1H), 6.84 (d, J = 8.4 Hz,
1H), 5.92−5.64 (m, 3H), 4.98 (s, 2H), 4.90−4.76 (m, 1H), 4.72−
4.55 (m, 2H), 4.55−4.44 (m, 1H), 3.90 (s, 3H), 3.55 (s, 3H), 3.44
(dt, J = 11.6, 5.8 Hz, 1H), 3.02 (d, J = 18.6 Hz, 1H), 2.83 (t, J = 5.7
Hz, 1H), 2.33−2.14 (m, 2H), 2.15−1.96 (m, 1H). UPLC: purity
>99%, m/z (ES) 491.2 [M + 1]. HRMS: calcd 490.18; found
491.1872 [M + 1].
(4aS,8aR)-4-(3,4-Dimethoxyphenyl)-2-(1-(thieno[3,2-d]-
pyrimidin-4-yl)azetidin-3-yl)-4a,5,8,8a-tetrahydrophthalazin-
1(2H)-one (60). Reagents: (4aS,8aR)-2-(azetidin-3-yl)-4-(3,4-dime-
thoxyphenyl)-4a,5,8,8a-tetrahydrophthalazin-1(2H)-one 2,2,2-trifluor-
oacetate (243.7 mg, 0.5 mmol), sodium hydride (25.7 mg, 1.1 mmol),
4-chlorothieno[3,2-d]pyrimidine (110 mg, 0.6 mmol), and DMF
anhydrous (2 mL). Reaction conditions: 1 h at 153 °C without the
alkyl agent and 16 h at 153 °C after the addition of the agent.
Purification: IsoleraOne using heptane/ethyl acetate as eluents,
followed by a second purification by IsoleraOne using water/
methanol as eluents. Yield: 10 mg, 4%. 1H NMR (400 MHz,
CDCl3) δ: 8.57 (s, 1H), 7.78 (d, J = 5.4 Hz, 1H), 7.46 (d, J = 5.4 Hz,
1H), 7.34 (d, J = 2.0 Hz, 1H), 7.23 (dd, J = 8.4, 2.1 Hz, 1H), 6.83 (d,
J = 8.4 Hz, 1H), 5.88 (ddd, J = 15.9, 8.0, 5.3 Hz, 1H), 5.84−5.68 (m,
2H), 4.94 (dd, J = 8.7, 5.1 Hz, 1H), 4.73 (dd, J = 16.8, 8.4 Hz, 2H),
4.60 (dd, J = 9.1, 5.3 Hz, 1H), 3.89 (s, 3H), 3.51−3.39 (m, 4H), 3.02
(d, J = 18.1 Hz, 1H), 2.84 (t, J = 5.7 Hz, 1H), 2.33−2.17 (m, 2H),
2.13−1.98 (m, 1H). UPLC: purity >99%, m/z (ES) 476.2 [M + 1].
HRMS: calcd 475.17; found 476.1756 [M + 1].
1-(2-(3-((4aS,8aR)-4-(3,4-Dimethoxyphenyl)-1-oxo-4a,5,8,8a-tet-
rahydrophthalazin-2(1H)-yl)azetidin-1-yl)-2-oxoethyl)-4,4-
dimethylpiperidine-2,6-dione (61). Reagents: (4aS,8aR)-2-(1-(2-
chloroacetyl)azetidin-3-yl)-4-(3,4-dimethoxyphenyl)-4a,5,8,8a-tetra-
hydrophthalazin-1(2H)-one (249 mg, 0.6 mmol), potassium carbo-
nate (247 mg, 1.8 mmol), 4,4-dimethylpiperidine-2,6-dione (126 mg,
0.9 mmol), and DMF (4 mL). Reaction conditions: 16 h at 100 °C
after the addition of the agent. Purification: IsoleraOne using water/
methanol as eluents. Yield: 180 mg, 58%. 1H NMR (400 MHz,
CDCl3) δ: 7.52 (s, 1H), 7.32 (dd, J = 8.5, 2.1 Hz, 1H), 6.90 (d, J = 8.5
Hz, 1H),5.63−5.83 (m, 3H), 4.65−4.13 (m, 6H), 3.93 (s, 6H), 3.37−
3.46 (m, 1H), 2.98 (d, J = 15.3 Hz, 1H), 2.77−2.84 (m, 1H), 2.54 (s,
4H), 2.31−1.90 (m, 3H), 1.16 (s, 6H). 13C NMR (100 MHz, CDCl3)
δ: 171.8, 167.9, 167.8, 166.5, 155.9, 155.6, 151.3, 149.6, 127.1, 127.0,
125.9, 125.8, 124.0, 124.0, 119.6, 119.5, 110.6, 110.6, 108.3, 108.2,
56.2, 56.1, 55.2, 54.9, 53.6, 53.4, 46.1, 44.9, 44.7, 38.8, 35.0, 34.9,
31.3, 29.5, 27.8, 23.7, 23.5, 22.3. UPLC: purity >99%, m/z (ES) 523.3
[M + 1]. HRMS: calcd 522.6; found 523.2557 [M + 1].
3-(2-(3-((4aS,8aR)-4-(3,4-Dimethoxyphenyl)-1-oxo-4a,5,8,8a-tet-
rahydrophthalazin-2(1H)-yl)azetidin-1-yl)-2-oxoethyl)-3-azaspiro-
[5.5]undecane-2,4-dione (62). Reagents: (4aS,8aR)-2-(1-(2-
chloroacetyl)azetidin-3-yl)-4-(3,4-dimethoxyphenyl)-4a,5,8,8a-tetra-
hydrophthalazin-1(2H)-one (245 mg, 0.6 mmol), 3-azaspiro[5.5]-
undecane-2,4-dione (159 mg, 0.9 mmol), potassium carbonate (243
mg, 1.8 mmol), and DMF (4 mL). Reaction conditions: 4 h at 100 °C
after the addition of the agent. Purification: IsoleraOne using water/
AcCN as eluents. Yield: 190 mg, 58%. 1H NMR (400 MHz, CDCl3)
δ: 7.58−7.53 (m, 1H), 7.31 (dd, J = 8.5, 2.1 Hz, 1H), 6.89 (d, J = 8.4
Hz, 1H), 5.82−5.62 (m, 3H), 4.66−4.18 (m, 6H), 3.94 (s, 3H), 3.92
(s, 3H), 3.37−3.46 (m, 1H), 2.98 (d, J = 17.0 Hz, 1H), 2.77−2.84
(m, 1H), 2.59 (d, J = 3.0 Hz, 4H), 1.94−2.30 (m, 3H), 1.49 (s, 8H),
1.43 (s, 2H). 13C NMR (100 MHz, CDCl3) δ: 171.8, 167.9, 167.8,
166.4, 155.9, 155.5, 151.3, 149.6, 127.1, 127.0, 126.0, 125.8, 124.0,
123.9, 119.6, 119.5, 110.6, 110.6, 108.3, 108.2, 56.2, 56.1, 55.2, 54.9,
53.6, 53.4, 44.9, 44.7, 43.8, 38.8, 36.1, 35.0, 34.9, 32.1, 31.4, 31.3,
25.8, 23.7, 23.5, 22.3, 21.6. UPLC: purity >99%, m/z (ES) 563.3 [M
+ 1]. HRMS: calcd 562.28; found 563.2870 [M + 1].
8-(2-(3-((4aS,8aR)-4-(3,4-Dimethoxyphenyl)-1-oxo-4a,5,8,8a-tet-
rahydrophthalazin-2(1H)-yl)azetidin-1-yl)-2-oxoethyl)-8-azaspiro-
[4.5]decane-7,9-dione (63). Reagents: (4aS,8aR)-2-(1-(2-
chloroacetyl)azetidin-3-yl)-4-(3,4-dimethoxyphenyl)-4a,5,8,8a-tetra-
hydrophthalazin-1(2H)-one (132 mg, 0.3 mmol), 8-azaspiro[4.5]-
decane-7,9-dione (80 mg, 0.5 mmol), potassium carbonate (131 mg,
0.9 mmol), and DMF (1 mL). Reaction conditions: 3 h at 100 °C
after the addition of the agent. Purification: IsoleraOne using
heptane/ethyl acetate as eluents. Yield: 139 mg, 80%. 1H NMR
(400 MHz, CDCl3) δ: 7.52 (d, J = 1.9 Hz, 1H), 7.32 (dd, J = 8.5, 2.1
Hz, 1H), 6.90 (d, J = 8.5 Hz, 1H), 5.84−5.62 (m, 3H), 4.68−4.16 (m,
6H), 3.98−3.88 (m, 6H), 3.42 (dt, J = 11.6, 5.8 Hz, 1H), 3.04−2.92
(m, 1H), 2.80 (t, J = 5.7 Hz, 1H), 2.63 (s, 4H), 2.32−2.12 (m, 2H),
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2.12−1.93 (m, 1H), 1.77−1.49 (m, 9H). 13C NMR (100 MHz,
CDCl3) δ: 172.1, 167.9, 166.4, 151.3, 149.6, 127.1, 125.9, 124.0,
119.6, 110.7, 108.4, 56.3, 56.1, 53.6, 44.9, 44.5, 39.6, 38.9, 37.7, 35.0,





4.9 mmol) was dissolved in anhydrous DCM (120 mL) under inert
atmosphere. Tribromoborane (2.4 mL, 24.6 mmol) was added very
slowly at −40 °C. The mixture was kept at this temperature during 1
h, and after that it was kept at rt for 2 h more. After that, the mixture
was poured onto ice−water and extracted with DCM (2 × 100 mL).
The crude was purified by IsoleraOne using methanol/water as
eluents obtaining the final compound (2.34 g, 99%). 1H NMR (400
MHz, CDCl3) δ: 8.54 (s, 1H), 7.75 (d, J = 5.6 Hz, 1H), 7.43 (d, J =
5.6 Hz, 1H), 7.33 (d, J = 2.1 Hz, 1H), 7.17 (dd, J = 8.4, 2.1 Hz, 1H),
6.88 (d, J = 8.4 Hz, 1H), 5.83−5.63 (m, 2H), 5.11−4.83 (m, 3H),
3.41−3.25 (m, 3H), 3.00 (d, J = 17.5 Hz, 1H), 2.76 (t, J = 5.8 Hz,
1H), 2.31−2.11 (m, 3H), 2.06−1.83 (m, 4H). 13C NMR (100 MHz,
CDCl3) δ: 167.2, 157.6, 155.1, 152.1, 152.0, 147.2, 145.1, 133.4,
126.7, 126.0, 124.1, 122.9, 118.6, 115.1, 114.3, 112.5, 51.4, 46.1, 45.9,
34.9, 31.2, 30.1, 29.4, 23.4, 22.5. UPLC: purity >99%, m/z (ES) 476.3
[M + 1]. HRMS: calcd 475.17; found 476.1756 [M + 1].
General Synthetic Procedure for Compounds 38 and 39.
The dimethoxy derivative (1 equiv) was dissolved in AcCN/water (10
mL:10 mL) and the solution was cooled down to −40 °C. Potassium
hydroxide (40 equiv) was added, and the mixture was kept at that
temperature during 30 min. After that time, bromodifluoromethyl-
diethylphosphonate (10 equiv) was added and the reaction was
stirred at −40 °C and at rt during a specified time for every reaction.
Diethyl ether was added, and the organic phase was purified by
IsoleraOne using different eluents, described in each reaction.
(4aS,8aR)-4-(3,4-Bis(difluoromethoxy)phenyl)-2-(1-(thieno[3,2-
d]pyrimidin-4-yl)piperidin-4-yl)-4a,5,8,8a-tetrahydrophthalazin-
1(2H)-one (38). Reagents: (4aS,8aR)-4-(3,4-dihydroxyphenyl)-2-(1-
(thieno[3,2-d]pyrimidin-4-yl)piperidin-4-yl)-4a,5,8,8a-tetrahydroph-
thalazin-1(2H)-one (719 mg, 1.5 mmol), potassium hydroxide (3 g,
60.5 mmol), and bromodifluoromethyldiethylphosphonate (2.7 mL,
15.1 mmol). Reaction conditions: 2 h at −40 °C and 16 h at rt.
Purification: IsoleraOne using heptane/ethyl acetate as eluents. Yield:
13.6 mg, 2%. 1H NMR (400 MHz, CDCl3) δ: 8.65 (s, 1H), 7.83 (d, J
= 5.5 Hz, 1H), 7.65−7.59 (m, 3H), 7.31−7.24 (m, 1H), 6.53 (td, J =
73.2, 6.7 Hz, 2H), 5.87−5.63 (m, 2H), 5.11−4.92 (m, 3H), 3.43−
3.21 (m, 3H), 3.08−2.92 (m, 1H), 2.82 (t, J = 5.8 Hz, 1H), 2.32−
2.11 (m, 3H), 2.11−1.86 (m, 4H). 13C NMR (100 MHz, CDCl3) δ:
167.0, 157.9, 152.6, 143.6, 142.3, 133.5, 133.0, 126.1, 124.2, 123.9,
123.6, 122.2, 120.3, 115.7 (t, J = 263.8 Hz), 115.6 (t, J = 263.8 Hz),
77.2, 52.5, 46.1, 34.8, 31.3, 30.3, 29.6, 23.2, 22.3. UPLC: purity >99%,
m/z (ES) 576.2 [M + 1].
(4aS,8aR)-4-(4-(Difluoromethoxy)-3-hydroxyphenyl)-2-(1-
(thieno[3,2-d]pyrimidin-4-yl)piperidin-4-yl)-4a,5,8,8a-tetrahy-
drophthalazin-1(2H)-one (39). Reagents: (4aS,8aR)-4-(3,4-dihydrox-
yphenyl)-2-(1-(thieno[3,2-d]pyrimidin-4-yl)piperidin-4-yl)-4a,5,8,8a-
tetrahydrophthalazin-1(2H)-one (700 mg, 1.5 mmol), potassium
hydroxide (3.3 g, 58.9 mmol), and bromodifluoromethyl-
diethylphosphonate (2.7 mL, 15.1 mmol). Reaction conditions: 45
min at −40 °C and 100 min at rt. Purification: IsoleraOne using
heptane/ethyl acetate as eluents. Yield: 18 mg, 2%. 1H NMR (400
MHz, CDCl3) δ: 8.63 (s, 1H), 7.76 (d, J = 5.5 Hz, 1H), 7.58 (d, J =
1.9 Hz, 1H), 7.50 (d, J = 5.5 Hz, 1H), 7.19 (dd, J = 8.5, 2.0 Hz, 1H),
7.15 (d, J = 8.5 Hz, 1H), 6.66 (t, J = 74.2 Hz, 1H), 5.86−5.64 (m,
2H), 5.10−4.80 (m, 3H), 3.41−3.25 (m, 3H), 3.03 (d, J = 19.2 Hz,
2H), 2.80 (t, J = 5.8 Hz, 1H), 2.23 (ddd, J = 16.5, 12.1, 4.0 Hz, 3H),
2.11−1.83 (m, 4H). 13C NMR (100 MHz, CDCl3) δ: 167.1, 158.0,
153.7, 153.5, 153.4, 148.7, 140.1 (t, J = 2.6 Hz), 133.3, 132.3, 126.1,
124.4, 123.9, 121.0, 117.9, 116.7 (t, J = 261.9 Hz), 114.6, 114.2, 52.0,
45.8, 45.6, 34.8, 31.3, 30.2, 29.4, 23.3, 22.4. UPLC: purity >99%, m/z
(ES) 526.2 [M + 1].
(3,4-Dimethoxyphenyl)imidazo[1,2-d][1,2,4]triazin-2-one (41).
Procedure was followed as previously described.28 A mixture of
(3,4-dimethoxyphenyl)(1H-imidazol-2-yl)methanone (200 mg, 0.2
mmol), ethyl hydrazinecarboxylate (161 mg, 0.3 mol), and
toluenesulfonic acid (14.7 mg, 0.02 mmol) in 4.3 mL of mesitylene
was refluxed for 2 h. While still hot, the clear brown solution was
decanted from a dark brown gum. On cooling, the crude was purified
by IsoleraOne using hexane and ethyl acetate as eluents, obtaining the
final compound (167.3 mg, 12%). 1H NMR (400 MHz, CDCl3) δ:
9.49 (s, 1H), 8.19 (dd, J = 8.5, 2.1 Hz, 1H), 7.97 (d, J = 1.4 Hz, 1H),
7.92 (d, J = 2.0 Hz, 1H), 7.70 (d, J = 1.4 Hz, 1H), 7.02 (d, J = 8.6 Hz,
1H), 4.00 (s, 3H), 3.97 (s, 3H). 13C NMR (100 MHz, DMSO-d6) δ:
150.4, 148.5, 144.6, 138.8, 137.3, 133.6, 125.0, 121.4, 114.3, 111.3,
110.5, 55.6, 55.5. UPLC: purity >99%, m/z (ES) 273.2 [M + 1].
HRMS: calcd 272.09; found 273.0988 [M + 1].
(3,4-Dimethoxyphenyl)(piperidin-4-yl)imidazo[1,2-d][1,2,4]-
triazin-2-one (42). tert-Butyl 4-((3,4-dimethoxyphenyl)-2-
oxoimidazo[1,2-d][1,2,4]triazinyl)piperidine-1-carboxylate (172.2
mg, 0.4 mmol) was dissolved in dichloromethane (5 mL). This
solution was cooled down to 0 °C. 2,2,2-Trifluoroacetic acid (0.3 mL,
3.8 mmol) was added, and the reaction was kept at rt 16 h. The
organic solvent was evaporated and the crude was purified by
IsoleraOne using water/methanol as eluents, obtaining the desired
compound (100 mg, 74%). 1H NMR (400 MHz, CDCl3) δ: 7.95−
7.79 (m, 3H), 7.59−7.44 (m, 1H), 6.86 (d, J = 8.5 Hz, 1H), 5.04−
4.88 (m, 1H), 3.83 (s, 3H), 3.80 (s, 3H), 3.47 (d, J = 12.6 Hz, 2H),
3.02 (t, J = 11.7 Hz, 2H), 2.51−2.29 (m, 2H), 2.06 (d, J = 13.6 Hz,
2H). 13C NMR (100 MHz, CDCl3) δ: 151.5, 149.1, 144.5, 139.4,
138.7, 134.7, 124.9, 122.2, 115.1, 111.5, 111.2, 56.2, 56.1, 53.3, 43.5,
27.5. UPLC: purity >99%, m/z (ES) 356.2 [M + 1]. HRMS: calcd
355.16.; found 356.1723 [M + 1].
General Synthetic Procedure for Compounds 44−49. Under
an inert atmosphere, alkene derivative (1 equiv) was dissolved in
anhydrous methanol. After this, Pd(C) (4 catalyst spatulas) was
added and the hydrogen atmosphere was connected to the flask,
leaving the reaction at room temperature for a specified time for each
reaction. The crude was filtered over a Celite pad, and the crude was
purified using the conditions described in every reaction.
(4aS,8aR)-2-(1-(2-Aminothieno[2,3-d]pyrimidin-4-yl)piperidin-4-
yl)-4-(3,4-dimethoxyphenyl)-4a,5,6,7,8,8a-hexahydrophthalazin-
1(2H)-one (44). Reagents: (4aS,8aR)-2-(1-(2-aminothieno[2,3-d]-
pyrimidin-4-yl)piperidin-4-yl)-4-(3,4-dimethoxyphenyl)-4a,5,8,8a-tet-
rahydrophthalazin-1(2H)-one (100 mg, 0.2 mmol) and anhydrous
methanol (10 mL). Reaction conditions: 3 days. Purification:
IsoleraOne using hexane/ethyl acetate as eluents. Yield: 12.5 mg,
12%. 1H NMR (400 MHz, CDCl3) δ: 7.38 (d, J = 2.0 Hz, 1H), 7.23
(dd, J = 8.5, 2.1 Hz, 1H), 7.21 (d, J = 6.2 Hz, 1H), 6.88 (d, J = 6.1 Hz,
1H), 6.85 (d, J = 8.5 Hz, 1H), 5.02 (tt, J = 11.4, 4.3 Hz, 1H), 4.86 (s,
2H), 4.76−4.63 (m, 2H), 3.91 (s, 3H), 3.83 (s, 3H), 3.29−3.14 (m,
2H), 3.13−3.01 (m, 1H), 2.71 (d, J = 3.2 Hz, 1H), 2.58 (d, J = 8.9
Hz, 1H), 2.23 (ddd, J = 24.8, 12.9, 4.4 Hz, 1H), 2.13−1.99 (m, 1H),
1.97−1.74 (m, 3H), 1.68 (s, 2H), 1.47−1.34 (m, 4H). 13C NMR (100
MHz, CDCl3) δ: 167.1, 159.5, 159.1, 153.2, 150.8, 149.3, 127.7,
121.0, 119.2, 116.4, 110.6, 110.5, 108.5, 56.1, 56.0, 52.2, 46.7, 46.7,
36.9, 35.7, 30.0, 29.4, 25.8, 24.7, 24.1, 22.1. UPLC: purity >99%, m/z
(ES) 521.3 [M + 1]. HRMS: calcd 520.23; found 521.2334 [M + 1].
3-(2-(4-((4aS,8aR)-4-(3,4-Dimethoxyphenyl)-1-oxo-4a,5,6,7,8,8a-
hexahydrophthalazin-2(1H)-yl)piperidin-1-yl)-2-oxoethyl)-3-
azaspiro[5.5]undecane-2,4-dione (45). Reagents: 3-(2-(4-
((4aS,8aR)-4-(3,4-dimethoxyphenyl)-1-oxo-4a,5,8,8a-tetrahydroph-
thalazin-2(1H)-yl)piperidin-1-yl)-2-oxoethyl)-3-azaspiro[5.5]-
undecane-2,4-dione (150 mg, 0.3 mmol), and anhydrous methanol
(25 mL). Reaction conditions: 3 h. Purification: no further
purification was needed. Yield: 120.3 mg, 80%. 1H NMR (400
MHz, CDCl3) δ: 7.44 (s, 1H), 7.27−7.22 (m, 1H), 6.87 (d, J = 8.5
Hz, 1H), 4.89 (t, J = 10.8 Hz, 1H), 4.73−4.52 (m, 3H), 3.97 (s, 3H),
3.92 (s, 3H), 3.27 (t, J = 14.5 Hz, 1H), 3.07 (dt, J = 9.9, 5.1 Hz, 1H),
2.87−2.52 (m, 7H), 2.20−1.28 (m, 22H). 13C NMR (101 MHz,
CDCl3) δ 171.9, 167.1, 164.9, 153.4, 150.9, 149.4, 127.7, 119.2, 110.6,
108.4, 56.3, 56.1, 52.0, 43.9, 40.5, 36.8, 36.2, 35.7, 32.1, 25.9, 25.8,
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24.7, 24.1, 22.1, 21.7. UPLC: purity >99%, m/z (ES) 593 [M + 1].
HRMS: calcd 592.33; found 593.3339 [M + 1].
1-(2-(4-((4aR,8aS)-4-(3,4-Difluorophenyl)-1-oxo-4a,5,6,7,8,8a-
hexahydrophthalazin-2(1H)-yl)piperidin-1-yl)-2-oxoethyl)-4,4-di-
methylpiperidine-2,6-dione (46). Reagents: 1-(2-(4-((4aR,8aS)-4-
(3,4-difluorophenyl)-1-oxo-4a,5,8,8a-tetrahydrophthalazin-2(1H)-yl)-
piperidin-1-yl)-2-oxoethyl)-4,4-dimethylpiperidine-2,6-dione (130
mg, 0.2 mmol) and anhydrous methanol (30 mL). Reaction
conditions: 3 h. Purification: precipitated in heptane at −78 °C.
Yield: 101 mg, 77%. 1H NMR (400 MHz, CDCl3) δ: 7.65 (ddd, J =
11.6, 7.7, 2.2 Hz, 1H), 7.53 (d, J = 7.1 Hz, 1H), 7.20 (dt, J = 9.7, 8.5
Hz, 1H), 4.89 (t, J = 10.6 Hz, 1H), 4.75−4.54 (m, 3H), 3.92 (t, J =
12.4 Hz, 1H), 3.25 (dd, J = 19.5, 9.1 Hz, 1H), 3.01 (dt, J = 9.9, 5.0
Hz, 1H), 2.82−2.62 (m, 2H), 2.56 (d, J = 15.7 Hz, 5H), 2.19−1.55
(m, 8H), 1.54−1.23 (m, 4H), 1.18 (d, J = 11.0 Hz, 6H). 13C NMR
(100 MHz, CDCl3) δ: 172.3, 167.1 (d, J = 2.8 Hz), 165.2 (d, J = 4.8
Hz), 152.8−151.9 (m), 151.4 (d, J = 22.4 Hz), 150.3, 132.1, 122.5,
117.7 (d, J = 17.6 Hz), 115.2 (dd, J = 18.6, 5.0 Hz), 52.3 (d, J = 2.8
Hz), 46.3, 44.4, 42.1, 40.5 (d, J = 4.7 Hz), 36.9 (d, J = 6.1 Hz), 35.8
(d, J = 6.5 Hz), 30.5, 29.7, 29.6, 29.1, 28.1, 25.8, 24.6 (d, J = 11.7 Hz),
24.1, 22.1. UPLC: purity >99%, m/z (ES) 529.3 [M + 1]. MP = 222−
224 °C. HRMS: calcd 528.25; found 529.2626 [M + 1].
3-(2-(4-((4aR,8aS)-4-(3,4-Difluorophenyl)-1-oxo-4a,5,6,7,8,8a-
hexahydrophthalazin-2(1H)-yl)piperidin-1-yl)-2-oxoethyl)-3-
azaspiro[5.5]undecane-2,4-dione (47). Reagents: 3-(2-(4-
((4aR,8aS)-4-(3,4-difluorophenyl)-1-oxo-4a,5,8,8a-tetrahydrophthala-
zin-2(1H)-yl)piperidin-1-yl)-2-oxoethyl)-3-azaspiro[5.5]undecane-
2,4-dione (105 mg, 0.2 mmol) and anhydrous methanol (30 mL).
Reaction conditions: 3 h. Purification: no further purification was
needed. Yield: 100 mg, 95%. 1H NMR (400 MHz, CDCl3) δ: 7.66
(ddd, J = 11.7, 7.7, 2.2 Hz, 1H), 7.54 (d, J = 8.0 Hz, 1H), 7.22 (dt, J =
9.8, 8.5 Hz, 1H), 4.90 (t, J = 10.9 Hz, 1H), 4.76−4.55 (m, 3H), 3.92
(t, J = 12.1 Hz, 1H), 3.27 (t, J = 14.0 Hz, 1H), 3.02 (dt, J = 10.0, 4.9
Hz, 1H), 2.85−2.47 (m, 6H), 2.21−1.21 (m, 23H). 13C NMR (100
MHz, CDCl3) δ: 172.3, 167.1 (d, J = 2.8 Hz), 165.2 (d, J = 4.8 Hz),
151.5 (dd, J = 252.0, 12.7 Hz), 151.4 (d, J = 22.4 Hz), 151.1 (dd, J =
179.9, 12.7 Hz), 132.1, 122.5, 117.7 (d, J = 17.6 Hz), 115.2 (dd, J =
18.6, 5.0 Hz), 52.1, 44.3, 43.9, 41.9, 40.5, 40.4, 36.8, 36.2, 35.7, 35.6,
32.1, 30.4, 29.6, 29.0, 25.9, 25.7, 24.5, 24.4, 24.0, 22.0, 21.7. UPLC:
purity >99%, m/z (ES) 569.3 [M + 1]. Mp = 222−224 °C.
1-(2-(4-((4aS,8aR)-4-(3,4-Dimethoxyphenyl)-1-oxo-4a,5,6,7,8,8a-
hexahydrophthalazin-2(1H)-yl)piperidin-1-yl)-2-oxoethyl)-4,4-
dimethylpiperidine-2,6-dione (48). Reagents: 1-(2-(4-((4aS,8aR)-4-
(3,4-dimethoxyphenyl)-1-oxo-4a,5,8,8a-tetrahydrophthalazin-2(1H)-
yl)piperidin-1-yl)-2-oxoethyl)-4,4-dimethylpiperidine-2,6-dione (370
mg, 0.7 mmol) and anhydrous methanol (20 mL). Reaction
conditions: 16 h. Purification: IsoleraOne using water/methanol as
eluents. Yield: 208.4 mg, 56%. 1H NMR (400 MHz, CDCl3) δ: 7.44
(dd, J = 6.0, 1.7 Hz, 1H), 7.24 (dd, J = 8.5, 2.0 Hz, 1H), 6.86 (d, J =
8.5 Hz, 1H), 4.89 (ddd, J = 15.3, 7.8, 3.9 Hz, 1H), 4.72−4.54 (m,
3H), 3.95 (s, 3H), 3.91 (s, 3H), 3.26 (td, J = 13.3, 5.1 Hz, 1H), 3.06
(dt, J = 10.0, 5.1 Hz, 1H), 2.74 (ddd, J = 10.5, 9.6, 4.9 Hz, 1H), 2.67
(s, 1H), 2.55 (s, 4H), 2.19−1.58 (m, 9H), 1.49−1.27 (m, 4H), 1.18
(s, 6H). 13C NMR (100 MHz, CDCl3) δ: 171.9, 167.1, 164.8, 164.5,
153.2, 150.7, 149.3, 127.6, 119.2, 110.5, 108.3, 56.2, 56.0, 51.9, 46.1,
44.2, 41.9, 40.4, 36.8, 35.6, 30.4, 29.5, 29.4, 28.9, 27.8, 25.7, 24.7,
24.5, 24.0, 22.0. UPLC: purity >99%, m/z (ES) 553.3 [M + 1].
HRMS: calcd 552.29; found 553.3031 [M + 1].
1-(2-(4-((4aS,8aR)-4-(3,4-Bis(difluoromethoxy)phenyl)-1-oxo-
4a,5,6,7,8,8a-hexahydrophthalazin-2(1H)-yl)piperidin-1-yl)-2-ox-
oethyl)-4,4-dimethylpiperidine-2,6-dione (49). Reagents: 1-(2-(4-
((4aS,8aR)-4-(3,4-bis(difluoromethoxy)phenyl)-1-oxo-4a,5,8,8a-tetra-
hydrophthalazin-2(1H)-yl)piperidin-1-yl)-2-oxoethyl)-4,4-dimethylpi-
peridine-2,6-dione (60 mg, 0.1 mmol) and anhydrous methanol (5
mL). Reaction conditions: 1 h. Purification: IsoleraOne using water/
methanol as eluents. Yield: 47.7 mg, 79%. 1H NMR (400 MHz,
CDCl3) δ: 7.68 (dd, J = 8.6, 2.1 Hz, 1H), 7.65 (d, J = 2.0 Hz, 1H),
7.32 (d, J = 8.6 Hz, 1H), 6.69 (t, J = 73.5 Hz, 2H), 6.77−6.37 (m,
2H), 4.92 (tt, J = 11.5, 4.1 Hz, 1H), 4.74−4.59 (m, 3H), 3.93 (t, J =
12.4 Hz, 1H), 3.27 (t, J = 12.0 Hz, 1H), 3.03 (dt, J = 10.2, 5.0 Hz,
1H), 2.83−2.66 (m, 2H), 2.59 (s, 4H), 2.21−1.55 (m, 8H), 1.55−
1.29 (m, 4H), 1.21 (s, 4H). 13C NMR (100 MHz, CDCl3) δ: 172.1,
167.0, 165.0, 164.9, 151.3, 143.3 (t, J = 2.9 Hz), 142.5 (t, J = 2.9 Hz),
133.7, 124.2, 122.3, 119.6, 115.9 (t, J = 262.5 Hz), 115.7 (t, J = 262.5
Hz), 77.2, 52.1, 46.2, 44.3, 42.0, 40.4, 36.8, 35.7, 30.4, 29.7, 29.7, 29.0,
27.9, 25.6, 24.5, 23.9, 22.0. UPLC: purity >99%, m/z (ES) 625.3 [M
+ 1].




(300 mg, 0.7 mmol) was stirred with triethylamine (0.3 mL, 2.3
mmol), potassium carbonate (105.0 mg, 0.8 mmol), and THF (3 mL)
during 1 h at rt After that, chloroacetyl chloride (0.7 mL, 0.9 mmol)
was added, and the reaction was kept at rt during 4 days.
Dichloromethane (50 mL) was added, and the reaction was washed
with brine (50 mL). The crude was purified by IsoleraOne using
dichloromethane/MeOH as eluents, obtaining the final product
(259.2 mg, 78%). 1H NMR (400 MHz, DMSO-d6) δ: 7.39 (d, J = 2.1
Hz, 2H), 7.01 (d, J = 9.0 Hz, 1H), 5.78−5.60 (m, 2H), 4.84−4.70 (m,
1H), 4.53−4.27 (m, 3H), 3.99−3.88 (m, 1H), 3.79 (s, 3H), 3.78 (s,
3H), 3.46 (dt, J = 11.6, 5.8 Hz, 1H), 3.27−3.14 (m, 1H), 2.89−2.70
(m, 3H), 2.12 (dt, J = 23.7, 17.7 Hz, 2H), 1.90−1.58 (m, 5H). UPLC:
purity >99%, m/z (ES) 446.2 [M + 1].
cis-6-(3-Chloro-4-methoxybenzoyl)cyclohex-3-enecarboxylic
Acid (18). Procedure was as previously reported:14 2-Chloroanisole
(1.7 mL, 13.2 mmol) was added dropwise to a suspension of
aluminum trichloride (2.1 g, 15.8 mmol) in DCM (20 mL) at 0 °C.
After stirring at this temperature for 30 min cis-3a,4,7,7a-
tetrahydroisobenzofuran-1,3-dione (2 g, 13.2 mmol) was added and
the reaction mixture was heated to reflux overnight. After that, the
reaction mixture was poured onto ice and extracted with DCM. The
organic phase was separated, dried over anhydrous Na2SO4, and
concentrated in vacuo. The crude product was purified by flash
column chromatography (Hept/EtOAc), obtaining the desired
compound (500 mg, 13%). 1H NMR (400 MHz, DMSO-d6) δ:
12.19 (s, 1H), 7.94−7.89 (m, 2H), 7.30−7.22 (m, 1H), 5.74−5.53
(m, 2H), 4.04−3.97 (m, 1H), 3.96 (d, J = 5.4 Hz, 3H), 2.89 (dt, J =
7.2, 3.9 Hz, 1H), 2.49−2.19 (m, 4H). UPLC: 1.61 min, m/z: 295 [M
+ 1] purity, 66%.
cis-6-(4-Fluorobenzoyl)cyclohex-3-enecarboxylic Acid (19). To
an ice-cooled solution of cis-3a,4,7,7a-tetrahydroisobenzofuran-1,3-
dione (1 g, 6.6 mmol) in THF (15 mL), (4-fluorophenyl)magnesium
bromide (6.6 mL, 6.6 mmol) was added dropwise, and the reaction
mixture was stirred 30 min at this temperature. Then it was allowed to
warm up and stirred 16 h at rt. The mixture was poured onto ice−
water and extracted with DCM (50 mL). Water layer was acidified
with HCl and extracted again with DCM (3 × 50 mL). The organic
phase was separated, dried over anh. N2SO4, filtered, and evaporated
(3 g, 92%). UPLC: purity = 94%, m/z (ES) 249.1 [M + 1].
cis-6-(3,4-Difluorobenzoyl)cyclohex-3-enecarboxylic Acid (20).
To an ice-cooled solution of cis-3a,4,7,7a-tetrahydroisobenzofuran-
1,3-dione (2 g, 13.2 mmol) in THF (30 mL), (3,4-difluorophenyl)-
magnesium bromide (13.2 mL, 6.6 mmol) was added dropwise, and
the reaction mixture was stirred 30 min at this temperature. Then it
was allowed to warm up and stirred 16 h at rt. The mixture was
poured onto ice−water and extracted with DCM (50 mL). Water
layer was acidified with HCl and extracted again with DCM (3 × 50
mL). The organic phase was separated, dried over anh. N2SO4,
filtered, and evaporated (3.1 g, 89%). UPLC: purity >99%, m/z (ES)
267.1 [M + 1].
cis-4-(3-Chloro-4-methoxyphenyl)-2-(piperidin-4-yl)-4a,5,8,8a-
tetrahydrophthalazin-1(2H)-one (21). To a suspension of cis-6-(3-
chloro-4-methoxybenzoyl)cyclohex-3-enecarboxylic acid (310 mg, 1.1
mmol) and 4-hydrazinylpiperidine (303 mg, 2.6 mmol) in EtOH (4
mL) was added triethylamine (0.7 mL, 5.3 mmol) at room
temperature, and the reaction mixture was stirred overnight at 80
°C. The crude was purified by IsoleraOne using ethyl acetate/
methanol as eluents. The unpure compound was used in the next step
without further purification (200 mg, 51%). UPLC: purity = 76%. m/
z (ES) 374.2 [M + 1].
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cis-4-(4-Fluorophenyl)-2-(piperidin-4-yl)-4a,5,8,8a-tetrahydroph-
thalazin-1(2H)-one (22). To a suspension of cis-6-(4-fluorobenzoyl)-
cyclohex-3-enecarboxylic acid (2 g, 8.1 mmol) and 4-hydrazinylpiper-
idine (2.3 g, 20.1 mmol) in EtOH (25 mL) was added triethylamine
(5.6 mL, 40.3 mmol) at room temperature, and the reaction mixture
was stirred overnight at 80 °C. The crude was purified by IsoleraOne
using heptane/ethyl acetate as eluents. The unpure compound was
used in the next step without further purification (1.5 g, 57%). UPLC:
purity = 66%. m/z (ES) 328.2 [M + 1]. 1H NMR (400 MHz, CDCl3)
δ: 7.90−7.76 (m, 2H), 7.12−6.97 (m, 2H), 5.83−5.49 (m, 2H), 4.80
(tt, J = 11.2, 3.9 Hz, 1H), 3.61−3.44 (m, 2H), 3.34−3.23 (m, 1H),
3.03−2.85 (m, 4H), 2.79−2.53 (m, 4H), 2.37 (ddd, J = 17.2, 13.4, 4.3
Hz, 2H), 2.23−2.05 (m, 3H), 1.97−1.77 (m, 3H).
cis-4-(3,4-Difluorophenyl)-2-(piperidin-4-yl)-4a,5,8,8a-tetrahy-
drophthalazin-1(2H)-one (23). To a suspension of cis-6-(3,4-
difluorobenzoyl)cyclohex-3-enecarboxylic acid (3 g, 11.3 mmol) and
4-hydrazinylpiperidine (3.2 mg, 28.2 mmol) in EtOH (4 mL) was
added triethylamine (7.8 mL, 56.3 mmol) at room temperature, and
the reaction mixture was stirred overnight at 80 °C. The crude was
purified by IsoleraOne using heptane/ethyl acetate as eluents. The
unpure compound was used in the next step without further





4a,5,8,8a-tetrahydrophthalazin-1(2H)-one (1.5 g, 3.4 mmol) was
dissolved in anhydrous DCM (120 mL), and under Ar atmosphere,
tribromoborane (1.6 mL, 16.8 mmol) was added carefully. The
reaction was kept at −40 °C during 30 min and at room temperature
for 30 min extra. The reaction was poured onto cold water and
extracted with DCM (50 mL). The crude was purified by IsoleraOne
using DCM/methanol as eluents (907 mg, 65%). 1H NMR (400
MHz, DMSO-d6) δ: 9.38 (d, J = 6.3 Hz, 1H), 9.19 (d, J = 4.9 Hz,
1H), 7.29 (dd, J = 9.2, 2.0 Hz, 1H), 7.11 (d, J = 8.3 Hz, 1H), 6.76 (d,
J = 8.3 Hz, 1H), 5.75−5.58 (m, 2H), 4.84−3.84 (m, 6H), 3.25−3.10
(m, 2H), 2.86−2.64 (m, 3H), 2.22−1.55 (m, 6H). UPLC: purity





mg, 1.3 mmol) was dissolved in water/AcCN (20 mL), and
potassium hydroxide (2.9 g, 52.6 mmol) was added at −40 °C.
Bromodifluoromethyldiethylphosphonate (2.3 mL, 13.2 mmol) was
added, and the temperature was kept at −40 °C. After 45 min, ethyl
ether (50 mL) and water (50 mL) were added. The organic phase was
dried oved sulfate magnesium and dried under vacuum. The crude
was purified by IsoleraOne using heptane/ethyl acetate as eluents
(185 mg, 27%). 1H NMR (400 MHz, CDCl3) δ: 7.73−7.55 (m, 2H),
7.27 (d, J = 8.6 Hz, 1H), 6.56 (t, J = 73.1 Hz, 2H), 5.84−5.57 (m,
2H), 4.86 (tt, J = 11.5, 4.1 Hz, 1H), 4.78−4.55 (m, 1H), 4.01−3.79
(m, 3H), 3.34−3.14 (m, 2H), 2.96 (d, J = 17.7 Hz, 1H), 2.81−2.64
(m, 2H), 2.27−1.63 (m, 7H). UPLC: purity >99%. m/z (ES) 518.1
[M + 1].
(3,4-Dimethoxyphenyl)(1H-imidazol-2-yl)methanone (40). Pro-
cedure was as previously described:25 A solution of imidazol and
triethylamine in pyridine at 0 °C is treated with 3,4-dimethoxybenzoyl
chloride, stirred for 5 min, allowed to warm up to rt, and kept at that
temperature for 16 h. After that the 7.5 N solution of NaOH was
added and the mixture was heated 2 h at 100 °C. Water and DCM
were added, and the organic phase was purified by IsoleraOne using
DCM/MeOH as eluents. 1H NMR (400 MHz, DMSO-d6) δ: 13.33
(s, 1H), 8.43 (dd, J = 8.5, 2.0 Hz, 1H), 8.08 (d, J = 2.0 Hz, 1H), 7.47
(d, J = 1.5 Hz, 1H), 7.28 (s, 1H), 7.13 (d, J = 8.6 Hz, 1H), 3.87 (s,
3H), 3.84 (s, 1H). UPLC: purity >99%. m/z (ES) 233.2 [M + 1].
6-(3,4-Dimethoxyphenyl)-2-(piperidin-4-yl)pyridazin-3(2H)-one
(50). 6-(3,4-Dimethoxyphenyl)-2,3-dihydropyridazin-3-one (1 g, 4.3
mmol) was solved in DMF anhydrous (5 mL), and sodium hydride
(0.1 g, 4.3 mmol) was added. The mixture was refluxed during 1 h.
After that, N-boc-4-bromopiperidine (2.3 g, 8.6 mmol) was added and
the reaction was kept 48 h. Ethyl acetate (50 mL) and a solution of
HCl 0.1 M (50 mL) were added, and the organic phase was washed
with a saturated solution of NaHCO3 (3 × 50 mL) and a saturated
solution of NaCl (3 × 50 mL). The obtained compound was used in
the next step without further purification or isolation (400 mg, 30%).
UPLC: purity = 60%. m/z (ES) 316.3 [M + 1].
Methyl 3-(3,4-Dimethoxyphenyl)-2,2-dimethyl-3-oxopropanoate
(52).30 Procedure was as previously described.26 Lithium diisopropy-
lamide (1.2 g, 1.8 M in THF, 10.9 mmol) was added to a dry three-
neck flask with 12.5 mL of anhydrous THF and cooled to −45 °C,
and methyl isobutyrate (1.7 mL, 14.9 mmol) was added dropwise.
The mixture was stirred for 30 min at −40 °C. 3,4-Dimethoxybenzoyl
chloride (2 g, 9.9 mmol) was dissolved in dry THF (12.5 mL) and
added dropwise during 30 min at −50 to −40 °C. The reaction
mixture was stirred for another 1 h before the cooling source was
removed, and the stirring continued at room temperature overnight.
The reaction mixture was acidified with 3 M HCl (aq) and diluted
with EtOAc (10 mL), and the aqueous layer was extracted with
EtOAc (2 × 10 mL). The combined organic layers were washed with
saturated NaHCO3 and brine, dried over MgSO4, and reduced in
vacuo. The crude product was purified with flash chromatography
using hexane and ethyl acetate as eluents to give the title compound
(950 mg, 36%). UPLC: purity >99%. m/z (ES) 267.2 [M + 1].
3-(3,4-Dimethoxyphenyl)-4,4-dimethyl-1H-pyrazol-5(4H)-one
(53).30 Procedure was as previously described.26 To methyl 3-(3,4-
dimethoxyphenyl)-2,2-dimethyl-3-oxopropanoate (950 mg, 3.06
mmol) dissolved in ethanol (10 mL) was added hydrazine hydrate
(357 mg, 7.1 mmol). The reaction mixture was stirred at 50 °C
overnight. The reaction mixture was cooled on ice and the precipitate
was filtered off over a glass filter, washed with cold ethanol, and dried
at 40 °C under vacuum to give the title compound as a solid foam




1.8 mmol) was dissolved in DMF anhydrous (3.5 mL), and sodium
hydride (89 mg, 3.7 mmol) was added. The mixture was at 153 °C for
30 min, and after that, tert-butyl 4-bromopiperidine-1-carboxylate
(734 mg, 1.5 mmol) was added. The reaction was kept at 153 °C
during 2 days. Ethyl acetate (50 mL) and a saturated solution of NaCl
(50 mL) were added, and the crude was purified by IsoleraOne using
hexane and ethyl acetate as eluents. The final compound was obtain
with a purity of 60%, and it was used in the next step without further
purification (143.9 mg, 18%). UPLC: purity >60%. m/z (ES) 376.2
[M + 1].
3-(3,4-Dimethoxyphenyl)-4,4-dimethyl-1-(piperidin-4-yl)-1H-pyr-
azol-5(4H)-one (55).30 tert-Butyl 4-(3-(3,4-dimethoxyphenyl)-4,4-
dimethyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)piperidine-1-carboxylate
(218.5 mg, 0.5 mmol) was dissolved in DCM at 0 °C. After that,
2,2,2-trifluoroacetic acid (577 mg, 5.0 mmol) was added and the
mixture was kept at rt for 3 h. The organic solvent was evaporated,
and the compound was used in the next step without further
purification (109.4 mg, 99%). UPLC: purity >55%. m/z (ES) 332.2
[M + 1].
(4aS,8aR)-2-(Azetidin-3-yl)-4-(3,4-dimethoxyphenyl)-4a,5,8,8a-
tetrahydrophthalazin-1(2H)-one (57). tert-Butyl 4-((3,4-dimethox-
yphenyl)-2-oxoimidazo[1,2-d][1,2,4]triazin-1-yl)piperidine-1-carbox-
ylate (733 mg, 1.7 mmol) was dissolved in DCM (3 mL) at 0 °C.
After that, 2,2,2-trifluoroacetic acid (1.3 mL, 17.6 mmol) was added,
and the mixture was stirred at 0 °C for 30 min. The reaction was kept
at room temperature overnight. The solvent was evaporated, and the
crude was used in the next step without further purification (243.7
mg, 43%). UPLC: purity = 70%, m/z (ES) 342.2 [M + 1].
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